# Author Search

```
   ⇨ FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 12:51:04 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 18 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008  (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

   ⇨ D STAT QUE L45
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(
                   HYDROXYMETHYL)-"/CN
L8          1204 SEA FILE=REGISTRY ABB=ON  PLU=ON  77-86-1/CRN
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC
                   ACID, 2-(4-FLUOROPHENYL)-B,Δ-DIHYDROXY-5-(1-METHYLET
                   HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,ΔR)-"/
                   CN
L10          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  134523-00-5/CRN
L12            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLO
                   ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
L13           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  49562-28-9/CRN
L14        10674 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L6 OR L8)
L15         4140 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L9 OR L10)
L16         1868 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L12 OR L13)
L17            9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 AND L15 AND L16
L28          406 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HOLM P?/AU
L29           32 SEA FILE=HCAPLUS ABB=ON  PLU=ON  NORLING T?/AU
L30            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L28 OR L29) AND L17
L44            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L28 OR L29) AND L17
L45            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L30 OR L44)
```

```
   ⇨ FILE BIOSIS EMBASE MEDLINE TOXCENTER DRUGU
FILE 'BIOSIS' ENTERED AT 12:51:45 ON 18 NOV 2008
Copyright I 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:51:45 ON 18 NOV 2008
Copyright I 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:51:45 ON 18 NOV 2008

FILE 'TOXCENTER' ENTERED AT 12:51:45 ON 18 NOV 2008
COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 12:51:45 ON 18 NOV 2008
COPYRIGHT I 2008 THOMSON REUTERS

   ⇨ D STAT QUE L31
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(
                   HYDROXYMETHYL)-"/CN
L8          1204 SEA FILE=REGISTRY ABB=ON  PLU=ON  77-86-1/CRN
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC
                   ACID, 2-(4-FLUOROPHENYL)-B,D-DIHYDROXY-5-(1-METHYLET
                   HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,DR)-"/
                   CN
L10          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  134523-00-5/CRN
L12            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLO
                   ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
L13           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  49562-28-9/CRN
L19        12476 SEA (L6 OR L8)
L20        18785 SEA (L9 OR L10)
L21         9094 SEA (L12 OR L13)
L22            8 SEA L19 AND L20 AND L21
L28          406 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HOLM P?/AU
L29           32 SEA FILE=HCAPLUS ABB=ON  PLU=ON  NORLING T?/AU
L31            0 SEA (L28 OR L29) AND L22


   ⇨ DUP REM L45 L31
L31 HAS NO ANSWERS
FILE 'HCAPLUS' ENTERED AT 12:52:12 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008  (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.
```

```
New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE
PROCESSING COMPLETED FOR L45
PROCESSING COMPLETED FOR L31
L51           1 DUP REM L45 L31 (0 DUPLICATES REMOVED)
                ANSWER '1' FROM FILE HCAPLUS

   ⇨  D IBIB ED ABS HITSTR L51 1

L51  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2006:818282  HCAPLUS  Full-text
DOCUMENT NUMBER:          145:235854
TITLE:                    A stable pharmaceutical composition comprising a fixed
                          dose combination of fenofibrate and an HMG-CoA
                          reductase inhibitor
INVENTOR(S):              Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S):       Lifecycle Pharma A/S, Den.
SOURCE:                   PCT Int. Appl., 31pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006084474         A2    20060817    WO 2006-DK50004         20060210
     WO 2006084474         A3    20061102
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2006212609         A1    20060817    AU 2006-212609          20060210
     CA 2597492            A1    20060817    CA 2006-2597492         20060210
     EP 1853249            A2    20071114    EP 2006-706137          20060210
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
     US 20080131503        A1    20080605    US 2006-582410          20060919
     MX 200709281          A     20070925    MX 2007-9281            20070801
     CN 101115478          A     20080130    CN 2006-80004608        20070810
     KR 2007104447         A     20071025    KR 2007-719786          20070830
     IN 2007CN03914        A     20071221    IN 2007-CN3914          20070910
PRIORITY APPLN. INFO.:                       DK 2005-200          A  20050210
                                             DK 2005-576          A  20050420
                                             WO 2006-DK50004      W  20060210
ED   Entered STN:  17 Aug 2006
```

AB A pharmaceutical composition for oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first and the second pharmaceutical compns. Are present in sep. entities in a single solid dosage form. For example a multilayer tablet, a two-layer tablet, or capsules or sachets contain the active ingredients in sep. granulates or beads, either granulate or bead optionally being coated with a protective coating or an entero-coating. Thus, a two-layer tablet was prepared comprising (i) fenofibrate granulate containing fenofibrate 145, PEG6000 189, Poloxamer 188 81, lactose 339, and Mg stearate 7.6, and (ii) atorvastatin granulate containing atorvastatin magnesium 44, mannitol 122, Mg stearate 1.5, Klucel 7, Polysorbate 80 2.4, Avicel 119, and trometamol 2.5 mg, resp. The resulting tablet had a weight of about 1060 mg.

IT 77-86-1 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable oral compns. Comprising fixed dose combination of fenofibrate and HMG-CoA reductase inhibitor)

RN 77-86-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



# Structure Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 12:52:28 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 18 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008  (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L17
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(
                   HYDROXYMETHYL)-"/CN
L8          1204 SEA FILE=REGISTRY ABB=ON  PLU=ON  77-86-1/CRN
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC
                   ACID, 2-(4-FLUOROPHENYL)-B,D-DIHYDROXY-5-(1-METHYLET
                   HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,DR)-"/
                   CN
L10          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  134523-00-5/CRN
L12            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLO
                   ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
L13           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  49562-28-9/CRN
L14        10674 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L6 OR L8)
L15         4140 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L9 OR L10)
L16         1868 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L12 OR L13)
L17            9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 AND L15 AND L16


=> S L17 NOT L45
L52            8 L17 NOT L45

=> FILE BIOSIS EMBASE MEDLINE TOXCENTER DRUGU
FILE 'BIOSIS' ENTERED AT 12:52:55 ON 18 NOV 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:52:55 ON 18 NOV 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.
```

```
FILE 'MEDLINE' ENTERED AT 12:52:55 ON 18 NOV 2008

FILE 'TOXCENTER' ENTERED AT 12:52:55 ON 18 NOV 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 12:52:55 ON 18 NOV 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

=> D STAT QUE L22
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(
                  HYDROXYMETHYL)-"/CN
L8          1204 SEA FILE=REGISTRY ABB=ON  PLU=ON  77-86-1/CRN
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC
                  ACID, 2-(4-FLUOROPHENYL)-B,D-DIHYDROXY-5-(1-METHYLET
                  HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,DR)-"/
                  CN
L10          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  134523-00-5/CRN
L12            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLO
                  ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
L13           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  49562-28-9/CRN
L19        12476 SEA (L6 OR L8)
L20        18785 SEA (L9 OR L10)
L21         9094 SEA (L12 OR L13)
L22            8 SEA L19 AND L20 AND L21


=> S L22 NOT L31
L53            8 L22 NOT L31

=> DUP REM L52 L53
FILE 'HCAPLUS' ENTERED AT 12:53:19 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 12:53:19 ON 18 NOV 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L52
PROCESSING COMPLETED FOR L53
L54            9 DUP REM L52 L53 (7 DUPLICATES REMOVED)
                  ANSWERS '1-8' FROM FILE HCAPLUS
                  ANSWER '9' FROM FILE TOXCENTER

=> D IBIB ED ABS HITSTR L54 1-8; D IALL 9 L54

L54  ANSWER 1 OF 9  HCAPLUS  COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2008:974067  HCAPLUS  Full-text
DOCUMENT NUMBER:          149:267913
TITLE:                    Preparation of quinoline compounds as modulators of
                          TGR5 for treatment of disease
INVENTOR(S):              Pinkerton, Anthony B.; Kabakibi, Ayman; Herbert, Mark
                          R.; Siegel, Dana L.
PATENT ASSIGNEE(S):       Kalypsys, Inc., USA
SOURCE:                   PCT Int. Appl., 186pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008097976 | A1 | 20080814 | WO 2008-US53056 | 20080205 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20080221161 | A1 | 20080911 | US 2008-26315 | 20080205 |
| PRIORITY APPLN. INFO.: | | | US 2007-889181P | P 20070209 |
| | | | US 2007-957516P | P 20070823 |

OTHER SOURCE(S): MARPAT 149:267913
ED Entered STN: 14 Aug 2008
GI




I




II

AB Disclosed herein are compds. of general formula I (wherein X is (CR9R10)m; Y is (CR11R12)n, etc.; m=0-2; n=0-3; R1 is aryl, heteroaryl, etc.; R2 is H, lower alkyl, etc.; R3 is H, amino, alkyl, etc.; R4, R5, R6, R7, and R8 are independently H, halo, OH, etc.; R9, R10, R11, R12 are independently H, lower alkyl, etc.) useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 7-methoxy-2-(thiophen-3-yl)quinoline-3- carboxaldehyde with (4-trifluoromethylphenyl)methanamine. In an assay measuring cAMP production by HEK293 cells expressing TGR5, II had an EC50 > 10μM.

IT 1185-53-1 49562-28-9 134523-00-5
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of quinoline compds. as modulators of TGR5 for treatment of disease)
RN 1185-53-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2008:673110 HCAPLUS Full-text
DOCUMENT NUMBER: 149:32334
TITLE: Preparation of diazepines and other heterocyclic modulators of TGR5 for treating metabolic, cardiovascular, and inflammatory diseases
INVENTOR(S): Pinkerton, Anthony B.; Kabakibi, Ayman; Gahman, Timothy C.
PATENT ASSIGNEE(S): Kalypsys, Inc., USA
SOURCE: PCT Int. Appl., 123pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008067222 | A1 | 20080605 | WO 2007-US85267 | 20071120 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-867583P P 20061128
OTHER SOURCE(S): MARPAT 149:32334
ED Entered STN: 06 Jun 2008
GI




I




II

AB The present invention relates to heterocyclic compds. of general formula I (wherein A is a 5-6-membered monocyclic heterocycloalkyl ring; X is O, S, etc.; Y is substituted N or C; Q1 and Q2 are N or substituted C; n is 0-2; R1 and R2 are independently null, acyl, alkyl, etc.;R3 is aryl, heteroaryl, etc.; R4 is a bond, H, halo, etc.; R5, R6, R7, R8 are independently H, alkyl, etc.) useful as modulators of TGR5 and methods for the treatment of prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 3,5-Bis(trifluoromethylphenylcarbonyl) chloride with 1-phenyl-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepine hydrochloride (preparation given). In an assay that measured cAMP production by HEK-293 cells transfected with TGR5, II had an EC50 of ≤ 10 μM.

IT 1185-53-1, T 6666 49562-28-9, Fenofibrate
134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of diazepines and other heterocyclic modulators of

TGR5
for treating metabolic, cardiovascular, and inflammatory diseases)
RN 1185-53-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2008:191482 HCAPLUS Full-text
DOCUMENT NUMBER: 148:246490
TITLE: Conveniently implantable sustained release drug compositions

INVENTOR(S): Wong, Vernon G.; Wood, Louis L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 54pp., Cont.-in-part of U.S. Ser. No. 236,426.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080038316 | A1 | 20080214 | US 2007-826833 | 20070718 |
| US 20060073182 | A1 | 20060406 | US 2005-236426 | 20050927 |
| AU 2005292145 | A1 | 20060413 | AU 2005-292145 | 20050927 |
| CA 2582096 | A1 | 20060413 | CA 2005-2582096 | 20050927 |
| EP 1793803 | A2 | 20070613 | EP 2005-804034 | 20050927 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| CN 101060831 | A | 20071024 | CN 2005-80039775 | 20050927 |
| JP 2008514719 | T | 20080508 | JP 2007-534731 | 20050927 |
| BR 2005016830 | A | 20080923 | BR 2005-16830 | 20050927 |
| MX 200703968 | A | 20080304 | MX 2007-3968 | 20070402 |
| IN 2007MN00515 | A | 20070803 | IN 2007-MN515 | 20070409 |
| KR 2007083901 | A | 20070824 | KR 2007-709976 | 20070501 |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 2004-614484P | P | 20041001 |
| US 2005-709665P | P | 20050819 |
| US 2005-236426 | A2 | 20050927 |
| US 2006-831991P | P | 20060719 |
| WO 2005-US34822 | W | 20050927 |

OTHER SOURCE(S): CASREACT 148:246490
ED Entered STN: 15 Feb 2008
AB This invention provides biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states. Thus, 760 mg of tri-Et O-acetyl citrate (TEAC) was mixed with 240 mg of dexamethasone (Dex) and 6 mg (25 μL) and 12 mg (25 μL) microdrops of this mixture were each incubated in 10 mL of 0.9% saline at 37°. A sustained release of dexamethasone from a formulation consisting of 24% Dex in TEAC was observed However, adding tocopherol acetate to the TEAC excipient at the ratio of 1:1 can extend the sustained release of therapeutic levels of Dex up to 450 days.
IT 49562-28-9, Fenofibrate 74103-07-4, Ketorolac tromethamine 134523-00-5, Atorvastatin
RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(injectable biocompatible and biodegradable implantable sustained release drug compns.)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 74103-07-4 HCAPLUS
CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 74103-06-3
CMF C15 H13 N O3



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2006:1339720 HCAPLUS Full-text

DOCUMENT NUMBER: 146:82189
TITLE: Preparation of L-threonine derivatives with high therapeutic index
INVENTOR(S): Chandran, V. Ravi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 60pp., Cont.-in-part of U.S. Ser. No. 343,557.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20060287244 | A1 | 20061221 | US 2006-442027 | 20060526 |
| WO 2005046575 | A2 | 20050526 | WO 2004-US24901 | 20040729 |
| WO 2005046575 | A3 | 20071004 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA | | | | |
| US 20060241017 | A1 | 20061026 | US 2006-343557 | 20060130 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2003-491331P | P | 20030729 |
| WO 2004-US24901 | A2 | 20040729 |
| US 2006-343557 | A2 | 20060130 |

OTHER SOURCE(S): CASREACT 146:82189
ED Entered STN: 22 Dec 2006
AB The invention is directed to novel therapeutic compds. comprised of an L-threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating function. These high-therapeutic index derivs. have the same utility as the drug from which they are made and they have enhanced pharmacol. and pharmaceutical properties, with the addnl. advantage of separating various enantiomeric and diastereomeric drugs into their individual isomers. The examples describe the synthesis and activities of L-threonine derivs. of (±)- and (+)-(S)-ibuprofen, (±)- and (+)-(S)-ketoprofen, (-)-(S)-ketorolac, aspirin, and fenofibric acid. The synthesis and activity of several L-serine and L-hydroxyproline analogs were also described. Thus, the hydrochloride of (+)-(S)-ibuprofen ester of L-threonine was prepared, and its free base examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.
IT 917472-08-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of L-threonine derivs. with high therapeutic index)
RN 917472-08-3 HCAPLUS
CN L-Threonine, ester with (βR,δR)-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (CA INDEX NAME)

CM 1

CRN 134523-00-5
CMF C33 H35 F N2 O5

Absolute stereochemistry.



CM 2

CRN 72-19-5
CMF C4 H9 N O3

Absolute stereochemistry.



IT 49562-28-9, Fenofibrate 74103-07-4 134523-00-5
, Atorvastatin
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of L-threonine derivs. with high therapeutic index)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 74103-07-4 HCAPLUS
CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 74103-06-3
CMF C15 H13 N O3



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2006:1124123 HCAPLUS Full-text
DOCUMENT NUMBER: 145:455276
TITLE: Preparation of amino acid derivatives with high therapeutic index
INVENTOR(S): Chandran, V. Ravi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 139pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20060241017 | A1 | 20061026 | US 2006-343557 | 20060130 |
| WO 2005046575 | A2 | 20050526 | WO 2004-US24901 | 20040729 |
| WO 2005046575 | A3 | 20071004 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

| | | | | |
|---|---|---|---|---|
| US 20060287244 | A1 | 20061221 | US 2006-442027 | 20060526 |
| WO 2007089745 | A2 | 20070809 | WO 2007-US2475 | 20070129 |
| WO 2007089745 | A3 | 20080821 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 2003-491331P | P | 20030729 |
| | WO 2004-US24901 | A2 | 20040729 |
| | US 2006-343557 | A2 | 20060130 |

ED Entered STN: 27 Oct 2006

AB The invention is directed to novel therapeutic compds. comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating function. These high-therapeutic index derivs. have the same utility as the drug from which they are made and they have enhanced pharmacol. and pharmaceutical properties. The examples describe the synthesis and activities of amino acid derivs. of propofol, ibuprofen, ketoprofen, ketorolac, aspirin, acetaminophen, cyclosporin A, valproic acid, clopidogrel, damazol, benzapril, enalapril, and fenofibric acid. Thus, (±)-ibuprofen esters of L-serine, L-threonine, and L-hydroxyproline were prepared and examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.

IT 74103-07-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid derivs. with high therapeutic index)

RN 74103-07-4 HCAPLUS

CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 74103-06-3
CMF C15 H13 N O3



CM 2

CRN 77-86-1
CMF C4 H11 N O3



IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. with high therapeutic index)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 20060024365 | A1 | 20060202 | US 2005-134633 | | 20050519 |
| IN 2002MU00697 | A | 20040529 | IN 2002-MU697 | | 20020805 |
| IN 193042 | A1 | 20040626 | | | |
| IN 2002MU00699 | A | 20040529 | IN 2002-MU699 | | 20020805 |
| IN 2003MU00080 | A | 20050204 | IN 2003-MU80 | | 20030122 |
| IN 2003MU00082 | A | 20050204 | IN 2003-MU82 | | 20030122 |
| US 20040096499 | A1 | 20040520 | US 2003-630446 | | 20030729 |
| PRIORITY APPLN. INFO.: | | | IN 2002-MU697 | A | 20020805 |
| | | | IN 2002-MU699 | A | 20020805 |
| | | | IN 2003-MU80 | A | 20030122 |
| | | | IN 2003-MU82 | A | 20030122 |
| | | | US 2003-630446 | A2 | 20030729 |

ED Entered STN: 03 Feb 2006
AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
IT 77-86-1, Trometamol 49562-28-9, Fenofibrate 109636-76-2, Prinomide tromethamine 134523-03-8, Atorvastatin calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)
RN 77-86-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 109636-76-2 HCAPLUS
CN 1H-Pyrrole-2-propanamide, α-cyano-1-methyl-β-oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8
CMF C15 H13 N3 O2



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:769872 HCAPLUS Full-text
DOCUMENT NUMBER: 148:387155
TITLE: Novel dosage form
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 96pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| IN 2005MU01013 | A | 20070629 | IN 2005-MU1013 | 20050826 |

PRIORITY APPLN. INFO.: IN 2005-MU1013 20050826
ED Entered STN: 17 Jul 2007
AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.
IT 77-86-1, Trometamol 49562-28-9, Fenofibrate 109636-76-2, Prinomide Tromethamine 134523-03-8, Atorvastatin Calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active ingredients)
RN 77-86-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 109636-76-2 HCAPLUS

CN 1H-Pyrrole-2-propanamide, α-cyano-1-methyl-β-oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8
CMF C15 H13 N3 O2



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




L54 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1016569 HCAPLUS Full-text
DOCUMENT NUMBER: 148:503081
TITLE: Novel drug delivery system
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| IN 2005MU01012 | A | 20070831 | IN 2005-MU1012 | 20050826 |
| PRIORITY APPLN. INFO.: | | | IN 2004-MU198 | A0 20040220 |

ED Entered STN: 12 Sep 2007
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
IT 77-86-1, Trometamol 49562-28-9, Fenofibrate 109636-76-2, Prinomide Tromethamine 134523-03-8, Atorvastatin Calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 77-86-1 HCAPLUS
CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)




RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 109636-76-2 HCAPLUS

CN 1H-Pyrrole-2-propanamide, α-cyano-1-methyl-β-oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8
CMF C15 H13 N3 O2



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




L54 ANSWER 9 OF 9 TOXCENTER COPYRIGHT 2008 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2008:54819 TOXCENTER Full-text
COPYRIGHT: Copyright 2008 ACS
DOCUMENT NUMBER: CA14822503081E
TITLE: Novel drug delivery system
AUTHOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
CORPORATE SOURCE: ASSIGNEE: Torrent Pharmaceuticals Limited
PATENT INFORMATION: IN 2005MU01012 A 31 Aug 2007
SOURCE: (2007) Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ.
COUNTRY: INDIA
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2007:1016569
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Feb 2008
Last Updated on STN: 29 Jul 2008
ABSTRACT:
A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
CLASSIFICATION CODE: 63-6
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
metformin niacin venlafaxine valproate tablet dissoln drug bioavailability
REGISTRY NUMBER: 404-86-4Q (Capsaicin, analogs)
13408-29-2 (Nitroxide)
70-18-8 (Glutathione)
9013-05-2 (Phosphatase)
9040-48-6 (Gelatinase)
79955-99-0 (Stromelysin 1)
120178-12-3 (Telomerase)
141256-52-2 (Matrilysin)
67-64-1 (Acetone)
75-09-2 (Methylene chloride)
1115-70-4 (Metformin hydrochloride)

REGISTRY NUMBER:
50-78-2 (Aspirin)
35425-83-3 (Quinuclium Bromide)
35449-36-6 (Gemcadiol)
35523-45-6 (Fludalanine)
35554-44-0 (Enilconazole)
35578-20-2 (Oxarbazole)
35604-67-2 (Viloxazine Hydrochloride)
35607-20-6 (Avridine)
35607-66-0 (Cefoxitin)
35700-23-3 (Carboprost)
35764-29-5 (Fluotracen Hydrochloride)
35795-17-6 (Trimazosin Hydrochloride)
35834-26-5 (Rosaramicin)
35838-58-5 (Etazolate Hydrochloride)
35846-53-8 (Maitansine)
35941-71-0 (Tiaramide Hydrochloride)
35943-35-2 (Triciribine)
36167-63-2 (Halofantrine Hydrochloride)
36282-47-0 (Tramadol hydrochloride)
36292-69-0 (Ketazocine)
36322-90-4 (Piroxicam)
36330-85-5 (Fenbufen)
36504-94-6 (Butaclamol Hydrochloride)
36505-82-5 (Prodolic Acid)
36508-71-1 (Zorubicin Hydrochloride)
36616-52-1 (Fenclorac)
36637-18-0 (Etidocaine)
36653-82-4 (Cetyl alcohol)
36735-22-5 (Quazepam)
36740-73-5 (Flumizole)
36791-04-5 (Ribavirin)
36945-03-6 (Lergotrile)
36950-96-6 (Cicloprofen)
36981-91-6 (Fepradinol)
36983-69-4 (Actodigin)
36983-81-0 (Fosfonet Sodium)
37087-94-8 (Tibric Acid)
37091-66-0 (Azlocillin)
37106-97-1 (Bentiromide)
37115-32-5 (Adinazolam)
37200-12-7 (Poly(isodecyl methacrylate))
37270-89-6 (Nadroparin calcium)
37321-09-8 (Apramycin)
37332-99-3 (Avoparcin)
37517-26-3 (Pipotiazine Palmitate)
37517-30-9 (Acebutolol)
37554-40-8 (Fluquazone)
37640-71-4 (Aprindine)
37661-08-8 (Bacampicillin Hydrochloride)
37686-84-3 (Terguride)
37717-21-8 (Flurocitabine)
37723-78-7 (Iopronic Acid)
37750-83-7 (Rimoprogin)
37751-39-6 (Ciclazindol)
37800-79-6 (Difenoximide Hydrochloride)
37863-70-0 (Iosumetic Acid)
38070-41-6 (Tiodonium Chloride)
38081-67-3 (Carmantadine)
38103-61-6 (Tolamolol)
38194-50-2 (Sulindac)

38241-28-0 (Zinterol Hydrochloride)
38241-39-3 (Tazolol Hydrochloride)
38270-90-5Q (Strontium chloride (89SrCl2), Sr 89)
38274-54-3 (Benurestat)
38304-91-5 (Minoxidil)
38363-32-5 (Penbutolol Sulfate)
38677-85-9 (Flunixin)
38821-53-3 (Cephradine)
38821-80-6 (Rodocaine)
38873-55-1 (Furobufen)
38955-22-5 (Pinadoline)
39022-39-4 (Oxaprotiline Hydrochloride)
39186-49-7 (Pirolazamide)
39236-46-9 (Imidurea)
39294-79-6 (Seractide Acetate)
39324-30-6 (Pepstatin)
39325-01-4 (Picibanil)
39562-70-4 (Nitrendipine)
39624-65-2 (Azanator Maleate)
39624-66-3 (Trepipam Maleate)
39698-78-7 (Saralasin Acetate)
39791-20-3 (Nylestriol)
39809-25-1 (Penciclovir)
39878-70-1 (Talampicillin Hydrochloride)
40034-42-2 (Rosoxacin)
40054-69-1 (Etizolam)
40180-04-9 (Ticrynafen)
40391-99-9 (Pamidronic acid)
40507-23-1 (Fluproquazone)
40594-09-0 (Flucindole)
40691-50-7 (Tixanox)
40759-33-9 (Nolinium Bromide)
40796-97-2 (Bemesetron)
40819-93-0 (Lorajmine Hydrochloride)
40828-44-2 (Clazolimine)
40828-45-3 (Azolimine)
40828-46-4 (Suprofen)
40966-79-8 (Sarpicillin)
41020-67-1 (Mexrenoate Potassium)
41020-79-5 (Dicirenone)
41078-02-8 (Enprofylline)
41094-88-6 (Tracazolate)
41113-86-4 (Bromoxanide)
41147-04-0 (Xanoxate Sodium)
41294-56-8 (Alfacalcidol)
41340-25-4 (Etodolac)
41570-61-0 (Tulobuterol)
41575-94-4 (Carboplatin)
41708-72-9 (Tocainide)
41767-29-7 (Fluocortin Butyl)
41859-67-0 (Bezafibrate)
41964-07-2 (Tolimidone)
41992-22-7 (Spirogermanium Hydrochloride)
42045-97-6 (Phenaridine)
42116-76-7 (Carnidazole)
42200-33-9 (Nadolol)
42220-21-3 (Iodocholesterol I 131)
42228-92-2 (Acivicin)
42281-59-4 (Oxilorphan)
42408-78-6 (Pirandamine Hydrochloride)

42408-82-2 (Butorphanol)
42422-68-4 (Taleranol)
42461-78-9 (Sulfonterol Hydrochloride)
42616-25-1 (Methioninase)
42779-82-8 (Clopirac)
42794-76-3 (Midodrine)
42835-25-6 (Flumequine)
42864-78-8 (Bevantolol Hydrochloride)
42877-18-9 (Pelanserin Hydrochloride)
42879-47-0 (Pranolium Chloride)
42924-53-8 (Nabumetone)
42971-09-5 (Vinpocetine)
43033-72-3 (Levomethadyl Acetate Hydrochloride)
43143-11-9 (Bispyrithione Magsulfex)
43200-80-2 (Zopiclone)
43210-67-9 (Fenbendazole)
47141-42-4 (Levobunolol)
49562-28-9 (Fenofibrate)

109636-76-2 (Prinomide Tromethamine)

134523-03-8 (Atorvastatin Calcium)
134564-82-2 (Befloxatone)
134633-29-7 (Tecogalan sodium)
134678-17-4 (Lamivudine)
134861-62-4 (Dioxamycin)
135038-56-1 (Glycopril)
135038-57-2 (Fasidotril)
135202-79-8 (Ilonidap)
135247-46-0 (Tylogenin)
135381-77-0 (Flezelastine)
135383-02-7 (Stipiamide)
REGISTRY NUMBER: 135459-90-4 (Ranelic acid)

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 12:54:17 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L50
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L26        2792 SEA FILE=REGISTRY SSS FUL L3
L35             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L37         321 SEA FILE=REGISTRY SUB=L26 SSS FUL L35
L38             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L39        1104 SEA FILE=REGISTRY SUB=L26 SSS FUL L38
L42         347 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L37 AND L39
L43         250 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L42 AND (PRY<=2005 OR
                AY<=2005 OR PY<=2005)
L46         152 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L43 AND 63/SC,SX
L49       49418 SEA FILE=HCAPLUS ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+NT/CT(L)
                (CAPSULE/OBI OR SACHET/OBI OR TABLET/OBI)
L50          60 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND L49
```

```
=> S L50 NOT L45,L52,L53
          7024 L6
          4045 L8
          3789 L9
           562 L10
          1868 L12
            13 L13
          7024 L6
          4045 L8
          3789 L9
           562 L10
          1868 L12
            13 L13
L55         56 L50 NOT (L45 OR L52 OR L53)

=> D IBIB ED ABS HITSTR L55 1-56

L55  ANSWER 1 OF 56  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:1188473  HCAPLUS  Full-text
DOCUMENT NUMBER:         149:432695
TITLE:                   Fenofibrate dosage forms
INVENTOR(S):             Ryde, Tuula A.; Gustow, Evan E.; Ruddy, Stephen B.;
                         Jain, Rajeev; Patel, Rakesh; Wilkins, Michael John;
                         Ryde, Niels P.
PATENT ASSIGNEE(S):      Elan Pharma International Ltd., Ire.; Fournier
                         Laboratories Ireland, Ltd.
SOURCE:                  U.S. Pat. Appl. Publ., 28pp., Cont.-in-part of U.S.
                         Ser. No. 846,144, abandoned.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  23
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------------    ----   --------    --------------------    --------
     US 20080241070       A1    20081002    US 2008-58497           20080328 <--
     US 6375986           B1    20020423    US 2000-666539          20000921 <--
     US 20020110597       A1    20020815    US 2002-75443           20020215 <--
     US 6592903           B2    20030715
     US 20040029099       A1    20040212    US 2002-323736          20021220 <--
     US 7198795           B2    20070403
     US 20030224058       A1    20031204    US 2003-370277          20030221 <--
     US 20050276974       A1    20051215    US 2003-444066          20030523 <--
     US 7276249           B2    20071002
PRIORITY APPLN. INFO.:                       US 2000-666539      A1 20000921 <--
                                             US 2002-75443       A2 20020215 <--
                                             US 2002-383294P     P  20020524 <--
                                             US 2002-323736      A2 20021220 <--
                                             US 2003-370277      A2 20030221 <--
                                             US 2003-444066      A2 20030523 <--
                                             US 2005-303024      B2 20051216 <--
                                             US 2005-275278      B2 20051221 <--
                                             US 2006-433823      B1 20060515
                                             US 2007-650579      B1 20070108
                                             US 2007-846144      B2 20070828
ED   Entered STN:  03 Oct 2008
AB    Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also
      disclosed are in vitro methods for evaluating the in vivo effectiveness of
      fibrate, such as fenofibrate, dosage forms.  The methods utilize media
```

representative of in vivo human physiol. conditions. Nanoparticulate fenofibrate formulations are prepared containing hypromellose and diocyl sodium succinate.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fenofibrate dosage forms)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 2 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:640693 HCAPLUS Full-text
DOCUMENT NUMBER: 149:1498
TITLE: Methods and compositions for controlling body weight and appetite
INVENTOR(S): Lippa, Arnold S.; Epstein, Joseph W.; Tizzano, Joseph T.; Basile, Anthony
PATENT ASSIGNEE(S): Dov Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008063673 | A1 | 20080529 | WO 2007-US24403 | 20071121 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, | | | | |

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

| | | | | | |
|---|---|---|---|---|---|
| US 20070225351 | A1 | 20070927 | US 2006-603974 | | 20061121 <-- |
| US 20080234354 | A1 | 20080925 | US 2007-943552 | | 20071120 |
| PRIORITY APPLN. INFO.: | | | US 2006-603974 | A | 20061121 |
| | | | US 2007-943552 | A | 20071120 |
| | | | WO 2002-US845 | W | 20020111 <-- |
| | | | US 2004-466457 | A1 | 20040210 <-- |
| | | | US 2006-442743 | A2 | 20060530 |

ED Entered STN: 29 May 2008

AB The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The methods and compns. of the invention may employ a (+)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for controlling body weight and appetite)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1309211 HCAPLUS Full-text
DOCUMENT NUMBER: 147:528186
TITLE: Nanoparticulate fibrate formulations
INVENTOR(S): Ryde, Tuula; Gustow, Evan E.; Jain, Rajeev; Patel, Rakesh; Wilkins, Michael John
PATENT ASSIGNEE(S): Elan Pharma International, Ltd., Ire.
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 522,528.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 23
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070264348 | A1 | 20071115 | US 2007-710607 | 20070226 <-- |
| US 20030224058 | A1 | 20031204 | US 2003-370277 | 20030221 <-- |
| US 20050276974 | A1 | 20051215 | US 2003-444066 | 20030523 <-- |
| US 7276249 | B2 | 20071002 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2002-383294P | P | 20020524 <-- |
| US 2003-370277 | A2 | 20030221 <-- |
| US 2003-444066 | A2 | 20030523 <-- |
| US 2005-275278 | B1 | 20051221 <-- |
| US 2006-522528 | B2 | 20060918 |

ED Entered STN: 16 Nov 2007
AB The present invention is directed to fibrate compns. having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. Thus, formulation was prepared containing fenofibrate 5%, hydroxypropyl cellulose 1%, and dioctyl sodium sulfosuccinate 0.05%.
IT 49562-28-9, Fenofibrate
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate fibrate formulations)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate fibrate formulations)
RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 4 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1088938 HCAPLUS Full-text
DOCUMENT NUMBER: 147:398709
TITLE: Methods and compositions for controlling body weight and appetite
INVENTOR(S): Lippa, Arnold S.; Epstein, Joseph W.; Basile, Anthony; Tizzano, Joseph T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27pp., Cont.-in-part of U.S. Ser. No. 442,743.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070225351 | A1 | 20070927 | US 2006-603974 | 20061121 <-- |
| WO 2002066427 | A2 | 20020829 | WO 2002-US845 | 20020111 <-- |
| WO 2002066427 | A3 | 20030313 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

```
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20040132797       A1    20040708    US 2004-466457         20040210 <--
     US 7098229           B2    20060829
     US 20080234354       A1    20080925    US 2007-943552         20071120
     WO 2008063673        A1    20080529    WO 2007-US24403        20071121
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                    WO 2002-US845       W  20020111 <--
                                          US 2004-466457      A1 20040210 <--
                                          US 2006-442743      A2 20060530
                                          US 2001-758883      A  20010111 <--
                                          US 2006-603974      A2 20061121
                                          US 2007-943552      A  20071120
```

ED Entered STN: 28 Sep 2007

AB The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The invention also provides novel compns. and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dyslipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compns. of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3- azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for controlling body weight and appetite)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:703828 HCAPLUS Full-text
DOCUMENT NUMBER: 147:102206
TITLE: Compressed solid dosage forms comprising drugs of low solubility and sugar and process for making the same
INVENTOR(S): Zalit, Ilan; Kopel, Mira
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007073389 | A1 | 20070628 | WO 2005-US47260 | 20051222 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| CA 2626234 | A1 | 20070628 | CA 2005-2626234 | 20051222 <-- |
| EP 1808163 | A1 | 20070718 | EP 2005-258010 | 20051222 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| IN 2008DN04349 | A | 20080815 | IN 2008-DN4349 | 20080522 <-- |

PRIORITY APPLN. INFO.: WO 2005-US47260 W 20051222 <--
ED Entered STN: 29 Jun 2007
AB One of the objects of the present invention is directed to a process of preparing a pharmaceutical formulation of a drug of low aqueous solubility, comprising (i) fixing the drug in a strong matrix comprising at least one at least partially amorphous sugar to obtain a sugar-drug matrix; and (ii)

milling the sugar-drug matrix to obtain a milled sugar-drug matrix as the pharmaceutical formulation. The invention also provides the pharmaceutical formulation prepared by the process. Thus, tablets containing 145 mg fenofibrate with improved drug dissoln. were prepared An amorphous sugar was prepared by mixing 644 mg sucrose with 322 μL water, heating the mixture to 125°, adding 128.8 mg glucose with continuous heating to 156°, cooling to room temperature and milling. The powder obtained was blended with fenofibrate 145 mg, sodium lauryl sulfate 50 mg, and PVP K30 100 mg and heated until the blend reached temperature of 60-80°, the mass was allowed to cool to room temperature, and then milled. Pregelatinized starch 217 mg, AcDiSol 50 mg, and Aerosil 200 13 mg were mixed, and then blended with the fenofibrate-containing powder, magnesium stearate 20 mg was added and the final blend was compressed into tablet.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and milling of matrix containing sugar and drug of low aqueous solubility
for compressed solid dosage forms)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 6 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:647596 HCAPLUS Full-text
DOCUMENT NUMBER: 147:58382
TITLE: Pharmaceutical tablets with height greater than width
INVENTOR(S): Solomon, Lawrence; Kaplan, Allan S.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S. Ser. No. 569,343.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070134321 | A1 | 20070614 | US 2006-561968 | 20061121 <-- |
| AU 2005245026 | A1 | 20051201 | AU 2005-245026 | 20050523 <-- |
| CA 2565029 | A1 | 20051201 | CA 2005-2565029 | 20050523 <-- |
| WO 2005112897 | A2 | 20051201 | WO 2005-US18633 | 20050523 <-- |
| WO 2005112897 | A3 | 20060921 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1755564 | A2 | 20070228 | EP 2005-754425 | 20050523 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| CN 1964703 | A | 20070516 | CN 2005-80016366 | 20050523 <-- |
| JP 2008500402 | T | 20080110 | JP 2007-527576 | 20050523 <-- |
| IN 2006KN03323 | A | 20070615 | IN 2006-KN3323 | 20061113 <-- |
| US 20080003285 | A1 | 20080103 | US 2006-569343 | 20061117 <-- |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| US 2004-573042P | P | 20040521 | <-- |
| US 2004-573134P | P | 20040521 | <-- |
| WO 2005-US18633 | W | 20050523 | <-- |
| US 2006-569343 | A2 | 20061117 | |

ED Entered STN: 15 Jun 2007

AB A compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet is described. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides. The layers can form a segment or, preferably, more than one segment. Thus, three segment, taller-than-wide tablets were prepared comprising (i) a bottom segment containing dibasic calcium phosphate 51.13, amlodipine besylate 7.15, Explotab 2.48, magnesium stearate 0.93, and FD&C Blue #1 Aluminum Lake 0.31, (ii) a middle segment containing Nu-Tab 194.00, and (iii) a top segment containing lactose monohydrate 42.03, benazepril HCl 9.00, Crospovidone 2.16, magnesium stearate 0.54, and FD&C Red #40 Aluminum Lake 0.27 mg, resp.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(taller-than-wide tablets with multiple layers and segments)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 7 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:644381 HCAPLUS Full-text

DOCUMENT NUMBER: 147:58365

TITLE: Therapeutic combinations comprising betaine and anti-cholesterol agent for reducing side effects on liver, pancreas and kidneys

INVENTOR(S): Messadek, Jallal

PATENT ASSIGNEE(S): Belg.

SOURCE: U.S. Pat. Appl. Publ., 16pp., Cont.-in-part of Appl. No. PCT/BE2006/000137.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070134324 | A1 | 20070614 | US 2007-625448 | 20070122 <-- |
| BE 1016128 | A6 | 20060307 | BE 2004-364 | 20040722 <-- |
| WO 2006007671 | A2 | 20060126 | WO 2005-BE112 | 20050713 <-- |
| WO 2006007671 | A3 | 20060223 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: BE 2004-364 A 20040722 <--
WO 2005-BE112 A2 20050713 <--
WO 2006-BE137 A2 20061222

ED Entered STN: 15 Jun 2007

AB The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and oral co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys. Such therapeutic combinations allow to augment the compliance of the pharmaceutical dosage form while retaining and respecting correct conservation properties. Thus, fenofibrate co-micronized with glycine betaine was mixed to an aqueous solution containing 20 wt% glycine betaine. The mixture was maintained under agitation for 10 min before being lyophilized as to obtain a dry product containing 15 wt% of fenofibrate and 85 wt% of glycine betaine. The product was ground to a powder with granulometry size <5 μm. Gelatin capsules were filled with 500 mg powder (75 mg of fenofibrate) and 750 powder mg (112.5 mg of fenofibrate).

IT 134523-03-8, Atorvastatin calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(betaine and anti-cholesterol agent therapeutic combinations for reducing side effects on liver, pancreas and kidneys)

RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




IT 49562-28-9, Fenofibrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(micronized, nanosized; betaine and anti-cholesterol agent therapeutic combinations for reducing side effects on liver, pancreas and kidneys)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



L55 ANSWER 8 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:620146 HCAPLUS Full-text
DOCUMENT NUMBER: 147:39188
TITLE: Composition comprising 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid
INVENTOR(S): Ju, Tzuchi R.; Engh, Kevin R.; Gao, Yi; Jayaraman, Shyamala C.; Lee, Dennis Y.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39pp., Cont.-in-part of U.S. Ser. No. 400,113.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070128278 | A1 | 20070607 | US 2006-549005 | 20061012 <-- |
| AU 2006258217 | A1 | 20061221 | AU 2006-258217 | 20060407 <-- |
| CA 2604078 | A1 | 20061221 | CA 2006-2604078 | 20060407 <-- |
| US 20070264334 | A1 | 20071115 | US 2006-400113 | 20060407 <-- |
| EP 1868587 | A2 | 20071226 | EP 2006-799902 | 20060407 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| JP 2008535851 | T | 20080904 | JP 2008-505585 | 20060407 <-- |
| MX 200712443 | A | 20071213 | MX 2007-12443 | 20071005 <-- |
| IN 2007DN07908 | A | 20071109 | IN 2007-DN7908 | 20071012 <-- |
| US 20080152714 | A1 | 20080626 | US 2007-871514 | 20071012 <-- |
| NO 2007005628 | A | 20071105 | NO 2007-5628 | 20071105 <-- |
| KR 2008008352 | A | 20080123 | KR 2007-726032 | 20071108 <-- |
| CN 101217944 | A | 20080709 | CN 2006-80020506 | 20071210 <-- |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 2005-669699P | P | 20050408 <-- |
| US 2006-400113 | A2 | 20060407 |
| US 2006-399964 | A2 | 20060407 |
| US 2006-399983 | A2 | 20060407 |
| WO 2006-US13121 | W | 20060407 |
| US 2006-548960 | A2 | 20061012 |
| US 2006-548982 | A2 | 20061012 |
| US 2006-549005 | A2 | 20061012 |
| US 2006-829255P | P | 20061012 |

ED Entered STN: 08 Jun 2007
AB The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. Thus, composition was containing 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic

acid 40%, dibasic calcium phosphate 15%, Avicel PH101 24%, PVP 30 5%, lactose monohydrate 15%, and magnesium stearate 1%.

IT 42017-89-0 42017-89-0D, salts 856676-23-8
RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition comprising 2-[4-(4-chlorobenzoyl)phenoxy]-2-Me-propanoic acid)

RN 42017-89-0 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 42017-89-0 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 856676-23-8 HCAPLUS
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-,
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate (1:1) (CA INDEX NAME)

CM 1

CRN 856676-22-7
CMF C17 H14 Cl O4



CM 2

CRN 62-49-7
CMF C5 H14 N O

IT 134523-00-5, Atorvastatin
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition comprising 2-[4-(4-chlorobenzoyl)phenoxy]-2-Me-propanoic acid)
RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 9 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:461081 HCAPLUS Full-text
DOCUMENT NUMBER: 146:415079
TITLE: Methods and compositions for treatment of prostate intraepithelial neoplasia
INVENTOR(S): Zweig, Jack I.
PATENT ASSIGNEE(S): Zweig, Jack, I., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007047553 | A2 | 20070426 | WO 2006-US40307 | 20061012 <-- |
| WO 2007047553 | A3 | 20080103 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-726753P P 20051014 <--
ED Entered STN: 27 Apr 2007

AB Provided herein are methods of treatment of prostate intraepithelial neoplasia (PIN) by administering bexarotene. Also provided are pharmaceutical compns. and dosing regimens.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of prostate intraepithelial neoplasia with bexarotene)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 10 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:63345 HCAPLUS Full-text

DOCUMENT NUMBER: 146:149041

TITLE: Granulation process for poorly water-soluble drugs

INVENTOR(S): Zalit, Ilan; Hrakovsky, Julia; Tenengauzer, Ruth; Shalom-Klein, Sagit

PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070014854 | A1 | 20070118 | US 2005-181822 | 20050715 <-- |
| CA 2614468 | A1 | 20070125 | CA 2005-2614468 | 20050715 <-- |

WO 2007011349 A1 20070125 WO 2005-US25326 20050715 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1793801 A1 20070613 EP 2005-772375 20050715 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
IN 2008DN00089 A 20080627 IN 2008-DN89 20080103 <--
CN 101222911 A 20080716 CN 2005-80051050 20080111 <--
PRIORITY APPLN. INFO.: US 2005-181822 A 20050715 <--
WO 2005-US25326 W 20050715 <--

ED Entered STN: 19 Jan 2007

AB One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one sugar, and optionally 1 excipient other than the sugar, wherein the API has a water solubility of <20 mg/mL. The excipient other than the sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosylpyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising 1 sugar, e.g., a pyranosylpyranose such as lactose, and a solvent, and optionally 1 excipient other than the sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b). Thus, a formulation contained bicalutamide 50.0, Avicel PH102 20.0, Aerosil-200 3.0, lactose monohydrate 30.8, Povidone 3.0, sodium starch glycolate 20.0, and Mg stearate 1.2 parts.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(granulation process for poorly water-soluble drugs)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 11 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:63188 HCAPLUS Full-text
DOCUMENT NUMBER: 146:149037
TITLE: Pharmaceutical granulate comprising pyranosyl pyranose
INVENTOR(S): Zalit, Ilan; Hrakovsky, Julia; Tenengauzer, Ruth; Shalom-Klein, Sagit
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries, Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070014864 | A1 | 20070118 | US 2005-181820 | 20050715 <-- |
| PRIORITY APPLN. INFO.: | | | US 2005-181820 | 20050715 <-- |

ED Entered STN: 19 Jan 2007
AB One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/mL. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate. For example, tablet was prepared containing bicalutamide 50, Avicel PH 102 20, Aerosil 200 3, lactose monohydrate 30.8, PVP k-3- 3, sodium starch glycolate 20 and magnesium stearate 1.2.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical granulate comprising pyranosyl pyranose)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 12 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:62910 HCAPLUS Full-text

DOCUMENT NUMBER: 146:149036

TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin

INVENTOR(S): Holm, Per; Norling, Tomas

PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.

SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of PCT/DK2005/050001.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070014846 | A1 | 20070118 | US 2006-456566 | 20060711 <-- |
| WO 2005034908 | A2 | 20050421 | WO 2004-DK668 | 20041001 <-- |
| WO 2005034908 | A3 | 20050811 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

```
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    US 20070009603       A1    20070111    US 2004-988917         20041115 <--
    WO 2006037344        A1    20060413    WO 2005-DK50001        20051003 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
            NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
            SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
            YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
    WO 2006037347        A1    20060413    WO 2005-DK50004        20051003 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
            NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
            SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
            YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
    US 20070190138       A1    20070816    US 2007-673270         20070209
PRIORITY APPLN. INFO.:                     DK 2003-1503        A  20031010 <--
                                           DK 2004-464         A  20040323 <--
                                           DK 2004-1506        A  20041001 <--
                                           WO 2004-DK668       A2 20041001 <--
                                           DK 2004-1761        A  20041115 <--
                                           US 2004-988917      A2 20041115 <--
                                           DK 2005-196         A  20050209 <--
                                           DK 2005-534         A  20050413 <--
                                           WO 2005-DK50001     A2 20051003 <--
                                           WO 2005-DK50004     A2 20051003 <--
                                           US 2006-790449P     P  20060407
                                           DK 2004-            A  20041223 <--
                                           DK 2006-203         A  20060210
ED   Entered STN:  19 Jan 2007
AB   Pharmaceutical compns. in particulate form or in solid dosage forms comprising
     a combination of fenofibrate and the HMG-CoA reductase inhibitor atorvastatin
     or a pharmaceutically active salt thereof, which upon oral administration
     provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between
     about 250 and about 10,000.  The solid compns. are manufactured without any
     need of addition of water or aqueous medium. Atorvastatin is optionally
     provided as a controlled-release or a delayed-release formulation resulting in
     a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is
     provided in a formulation having increasing bioavailability and reduced food
     effect.
IT   49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
```

134523-03-8, Atorvastatin calcium 344423-98-9
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 344423-98-9 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, hydrate (2:1:3), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 13 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:41338 HCAPLUS Full-text
DOCUMENT NUMBER: 146:128665
TITLE: Compositions comprising fenofibrate and atorvastatin
INVENTOR(S): Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S): Den.
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of Appl. No. PCT/DK04/000668.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20070009603 | A1 | 20070111 | US 2004-988917 | 20041115 <-- |
| WO 2005034908 | A2 | 20050421 | WO 2004-DK668 | 20041001 <-- |
| WO 2005034908 | A3 | 20050811 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| US 20070026062 | A1 | 20070201 | US 2006-449918 | | 20060609 <-- |
| US 20070014846 | A1 | 20070118 | US 2006-456566 | | 20060711 <-- |
| PRIORITY APPLN. INFO.: | | | DK 2003-1503 | A | 20031010 <-- |
| | | | DK 2004-464 | A | 20040323 <-- |

| | | |
|---|---|---|
| WO 2004-DK668 | A2 | 20041001 <-- |
| DK 2004-1506 | A | 20041001 <-- |
| DK 2004-1761 | A | 20041115 <-- |
| US 2004-988917 | A2 | 20041115 <-- |
| DK 2005-196 | A | 20050209 <-- |
| DK 2005-527 | A | 20050413 <-- |
| DK 2005-534 | A | 20050413 <-- |
| WO 2005-DK50001 | A2 | 20051003 <-- |
| WO 2005-DK50004 | A2 | 20051003 <-- |
| US 2006-787472P | P | 20060329 |
| US 2006-790449P | P | 20060407 |

ED Entered STN: 12 Jan 2007

AB The present invention relates to pharmaceutical compns. in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compns. are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and atorvastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability. Thus, immediate release tablet was prepared containing fenofibrate 23.9%, atorvastatin 1.5%, lactose 37.6%, PEG 25.6%, Poloxamer 188 11%, and magnesium stearate 0.4%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



IT 344920-08-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising fenofibrate and atorvastatin)
RN 344920-08-7 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, hydrate (2:1:6), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 14 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:343940 HCAPLUS Full-text
DOCUMENT NUMBER: 144:376530
TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin
INVENTOR(S): Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006037344 | A1 | 20060413 | WO 2005-DK50001 | 20051003 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| CA 2582403 | A1 | 20060413 | CA 2005-2582403 | 20051003 <-- |

| | | | | | |
|---|---|---|---|---|---|
| EP 1804769 | A1 | 20070711 | EP 2005-789004 | | 20051003 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | | |
| US 20070026062 | A1 | 20070201 | US 2006-449918 | | 20060609 <-- |
| US 20070014846 | A1 | 20070118 | US 2006-456566 | | 20060711 <-- |
| IN 2007CN01883 | A | 20070831 | IN 2007-CN1883 | | 20070503 <-- |
| PRIORITY APPLN. INFO.: | | | DK 2004-1506 | A | 20041001 <-- |
| | | | DK 2004-1761 | A | 20041115 <-- |
| | | | DK 2004- | A | 20041223 <-- |
| | | | DK 2005-196 | A | 20050209 <-- |
| | | | DK 2005-534 | A | 20050413 <-- |
| | | | DK 2003-1503 | A | 20031010 <-- |
| | | | DK 2004-464 | A | 20040323 <-- |
| | | | WO 2004-DK668 | A2 | 20041001 <-- |
| | | | US 2004-988917 | A2 | 20041115 <-- |
| | | | DK 2005-527 | A | 20050413 <-- |
| | | | WO 2005-DK50001 | W | 20051003 <-- |
| | | | WO 2005-DK50004 | A2 | 20051003 <-- |
| | | | US 2006-787472P | P | 20060329 |
| | | | US 2006-790449P | P | 20060407 |

ED Entered STN: 14 Apr 2006

AB Pharmaceutical compns. are disclosed in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compns. are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 15 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:343414 HCAPLUS Full-text
DOCUMENT NUMBER: 144:376521
TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin
INVENTOR(S): Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006037347 | A1 | 20060413 | WO 2005-DK50004 | 20051003 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| CA 2582405 | A1 | 20060413 | CA 2005-2582405 | 20051003 <-- |
| EP 1804768 | A1 | 20070711 | EP 2005-789000 | 20051003 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| US 20070026062 | A1 | 20070201 | US 2006-449918 | 20060609 <-- |
| US 20070014846 | A1 | 20070118 | US 2006-456566 | 20060711 <-- |
| IN 2007CN01880 | A | 20070831 | IN 2007-CN1880 | 20070503 <-- |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| DK 2004-1506 | A | 20041001 <-- | |
| DK 2004-1761 | A | 20041115 <-- | |
| DK 2004- | A | 20041223 <-- | |
| DK 2005-196 | A | 20050209 <-- | |
| DK 2005-534 | A | 20050413 <-- | |
| DK 2003-1503 | A | 20031010 <-- | |
| DK 2004-464 | A | 20040323 <-- | |
| WO 2004-DK668 | A2 | 20041001 <-- | |

| | | |
|---|---|---|
| US 2004-988917 | A2 | 20041115 <-- |
| DK 2005-527 | A | 20050413 <-- |
| WO 2005-DK50001 | A2 | 20051003 <-- |
| WO 2005-DK50004 | W | 20051003 <-- |
| US 2006-787472P | P | 20060329 |
| US 2006-790449P | P | 20060407 |

ED Entered STN: 14 Apr 2006

AB Pharmaceutical compns. are disclosed in particulate form or in solid dosage forms comprising a combination of a reduced or low dose of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof. Atorvastatin is optionally provided as a controlled release or a delayed release formulation, which may result in a maintained LDL-lowering effect at a reduced dosage. Fenofibrate is provided in a formulation being bioequivalent to com. available Antara capsules, or exhibiting increased bioavailability as compared thereto, and also reduced food effect.

IT 49562-28-9, Antara 134523-00-5, Atorvastatin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 16 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:76446 HCAPLUS Full-text
DOCUMENT NUMBER: 144:156741
TITLE: Therapeutic combinations containing a betaine and an

anticholesterol agent
INVENTOR(S): Messadek, Jallal
PATENT ASSIGNEE(S): Belg.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006007671 | A2 | 20060126 | WO 2005-BE112 | 20050713 <-- |
| WO 2006007671 | A3 | 20060223 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| BE 1016128 | A6 | 20060307 | BE 2004-364 | 20040722 <-- |
| EP 1773450 | A2 | 20070418 | EP 2005-763958 | 20050713 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| US 20070134324 | A1 | 20070614 | US 2007-625448 | 20070122 <-- |
| PRIORITY APPLN. INFO.: | | | BE 2004-364 A | 20040722 <-- |
| | | | WO 2005-BE112 W | 20050713 <-- |
| | | | WO 2006-BE137 A2 | 20061222 |

ED Entered STN: 27 Jan 2006

AB The invention relates to a pharmaceutical composition containing a betaine and an anti-cholesterol agent. The association and co-administration of at least one type of betaine makes it possible to reduce secondary effects accompanying the administration of anticholesterol agents, in particular harmful effects on the liver, pancreas and kidney. A tablet contained anhydrous betaine 350.00, micronized fenofibrate (5-20 μm) 60.00, lactose 35.00, Et cellulose 90.00, cetostearyl alc. 32.00, magnesium stearate 17.00, and talc 16.00 mg.

IT 49562-28-9, Fenofibrate 134523-03-8, Atorvastatin calcium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations containing betaine and anticholesterol agent)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-03-8 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 17 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:7329 HCAPLUS Full-text
DOCUMENT NUMBER: 144:94360
TITLE: Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
INVENTOR(S): Udell, Ronald G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 145,563.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20060003947 | A1 | 20060105 | US 2005-176593 | 20050707 <-- |
| US 20050249803 | A1 | 20051110 | US 2005-145563 | 20050603 <-- |
| WO 2006132879 | A2 | 20061214 | WO 2006-US21079 | 20060530 <-- |
| WO 2006132879 | A3 | 20070823 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-145563 A2 20050603 <--
US 2005-176593 A 20050707 <--
ED Entered STN: 05 Jan 2006

AB The present invention is directed to soft gel compns., methods of delivery and packaged nutraceuticals of the soft gel compns. that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Optional active ingredients include a phytosterol, DHA, EPA, coenzyme Q-10 or an analog thereof and mixts. thereof.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 18 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1201058 HCAPLUS Full-text
DOCUMENT NUMBER: 143:446808
TITLE: Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
INVENTOR(S): Udell, Ronald G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| US 20050249803 | A1 | 20051110 | US 2005-145563 | 20050603 <-- |
| US 20060003947 | A1 | 20060105 | US 2005-176593 | 20050707 <-- |
| WO 2006132879 | A2 | 20061214 | WO 2006-US21079 | 20060530 <-- |
| WO 2006132879 | A3 | 20070823 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | US 2005-145563 | A2 | 20050603 <-- |
| | US 2005-176593 | A | 20050707 <-- |

ED Entered STN: 11 Nov 2005

AB The present invention is directed to soft gel compns., methods of delivery and packaged nutraceuticals of the soft gel compns. that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Serum samples obtained from healthy subjects following oral administration of 2 different Sytrinol formulations contained detectable amts. of tangeretin and nobiletin.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 19 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1004560 HCAPLUS Full-text
DOCUMENT NUMBER: 143:292574
TITLE: Co-formulations of kits of bioactive agents
INVENTOR(S): Borsadia, Suresh
PATENT ASSIGNEE(S): Abeille Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2005084666 | A1 | 20050915 | WO 2005-US6043 | | 20050228 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| EP 1734953 | A1 | 20061227 | EP 2005-714070 | | 20050228 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | | |
| JP 2007526309 | T | 20070913 | JP 2007-501850 | | 20050228 <-- |
| US 20070098778 | A1 | 20070503 | US 2006-595884 | | 20060518 <-- |
| PRIORITY APPLN. INFO.: | | | US 2004-549420P | P | 20040302 <-- |
| | | | WO 2005-US6043 | W | 20050228 <-- |

ED Entered STN: 16 Sep 2005
AB A formulation or kit is provided comprising: (a) 1 or more glucose-level-controlling bioactive agents selected from an α-glucosidase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPAR α/γ agonist, PPAR α/γ agonist or insulin secretagogue; and (b) an antihypertensive selected from an ACE inhibitor, calcium channel blocker, β-blocker, angiotensin II receptor antagonist or diuretic, or one or more of an anti-dyslipidemia agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative In the case of a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group

(a) that is a thiazolidinedione or dual PPAR α/γ agonist with an angiotensin II receptor antagonist, one or more of the following applies: one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or the co-formulation or kit comprises a biguanide and a thiazolidinedione and one or more group (b) bioactive agents. Thus, a formulation contained metformin-HCl 66.7, microcryst. cellulose 16.7, and Eudragit NE40D 16.7%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-formulations of kits of bioactive agents)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 20 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1001853 HCAPLUS Full-text

DOCUMENT NUMBER: 143:311933

TITLE: Compositions of bioactive compounds from Fenugreek seed and methods for producing same

INVENTOR(S): Lee, Steve S.; Hynson, Richard B.; Zhang, Ke-Qin; Li, Wu-Zhou; Zhou, Jing Shi

PATENT ASSIGNEE(S): Technical Sourcing International, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| WO 2005084323 | A2 | 20050915 | WO 2005-US6676 | | 20050302 | <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | | |
| US 20050233013 | A1 | 20051020 | US 2005-68734 | | 20050301 | <-- |
| US 20050233014 | A1 | 20051020 | US 2005-69836 | | 20050301 | <-- |
| US 20050238738 | A1 | 20051027 | US 2005-69747 | | 20050301 | <-- |
| PRIORITY APPLN. INFO.: | | | US 2004-549198P | P | 20040302 | <-- |
| | | | US 2005-68734 | A | 20050301 | <-- |
| | | | US 2004-549305P | P | 20040302 | <-- |

ED Entered STN: 15 Sep 2005

AB The present invention is directed to novel compns. of bioactive compds. comprising 4-hydroxyisoleucine and one or more compds. selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compns. of bioactive compds. include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, and gamma-aminobutyrate. The composition of bioactive compds. preferably include about 10 to 70% of 4-hydroxyisoleucine and about 20 to 40% of other amino acids. The bioactive compds. of the novel composition of the present invention may be derived, isolated, and/or extracted from Fenugreek seeds. A preferred method for extracting the bioactive compds. from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bioactive compds. from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compns. of bioactive compds. have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination with; preparation of compns. of bioactive compds. from Fenugreek seed affecting homeostasis and metabolism)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 21 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:823553 HCAPLUS Full-text
DOCUMENT NUMBER: 143:199940
TITLE: Combination drug containing antihyperlipidemics and α-glucosidase inhibitors
INVENTOR(S): Kanazawa, Hashime; Ishitani, Kouki; Sudo, Katsuichi; Tanimori, Naoto
PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2005074909 | A1 | 20050818 | WO 2005-JP1801 | | 20050208 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2555316 | A1 | 20050818 | CA 2005-2555316 | | 20050208 <-- |
| EP 1714648 | A1 | 20061025 | EP 2005-709853 | | 20050208 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | | |
| US 20070197602 | A1 | 20070823 | US 2006-588725 | | 20060808 <-- |
| PRIORITY APPLN. INFO.: | | | JP 2004-32329 | A | 20040209 <-- |
| | | | WO 2005-JP1801 | W | 20050208 <-- |

ED Entered STN: 19 Aug 2005

AB Disclosed is a drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compds. (fenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase inhibitors (statin compds. such as pravastatin, atorvastatin, salts thereof, etc.) with an α-glucosidase inhibitor (voglibose, acarbose, etc.). The content of the α-glucosidase inhibitor may be from 0.001 to 50 parts by weight per 100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to provide a drug having excellent effects of preventing and/or treating metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc. with little side effect. For example, the effect of combination of fenofibrate and voglibose was examined in streptozotocin-induced diabetic rats. Also, a tablet containing fenofibrate 100, voglibose 0.2, lactose 69.2, fine crystalline cellulose 29.6, magnesium stearate 1 mg was formulated.

IT 861998-84-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination drug containing antihyperlipidemics and α-glucosidase inhibitors)

RN 861998-84-7 HCAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-, mixt. with 1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate (9CI) (CA INDEX NAME)

CM 1

CRN 83480-29-9

CMF C10 H21 N O7

Absolute stereochemistry. Rotation (+).




CM 2

CRN 49562-28-9

CMF C20 H21 Cl O4



IT 42017-89-0, Fenofibric acid 49562-28-9, Fenofibrate
134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination drug containing antihyperlipidemics and α-glucosidase inhibitors)
RN 42017-89-0 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 22 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:523236 HCAPLUS Full-text

DOCUMENT NUMBER: 143:48119
TITLE: Reverse micelle formulations comprising one or more surfactant, a hydrophilic phase and lipophilic or hydrophobic compounds
INVENTOR(S): Liang, Likan
PATENT ASSIGNEE(S): Shire Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005053612 | A2 | 20050616 | WO 2004-US39567 | 20041124 <-- |
| WO 2005053612 | A3 | 20050915 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2537029 | A1 | 20050616 | CA 2004-2537029 | 20041124 <-- |
| US 20050191343 | A1 | 20050901 | US 2004-995942 | 20041124 <-- |
| EP 1706098 | A2 | 20061004 | EP 2004-812147 | 20041124 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| JP 2007512373 | T | 20070517 | JP 2006-541711 | 20041124 <-- |

PRIORITY APPLN. INFO.:
US 2003-525572P P 20031126 <--
US 2004-541389P P 20040202 <--
US 2004-566157P P 20040428 <--
WO 2004-US39567 W 20041124 <--

ED Entered STN: 17 Jun 2005

AB The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compds., particularly therapeutic compds. The formulations contains one or more non-ionic surfactants or a mixture of nonionic and ionic surfactants, a hydrophilic phase composed of one or more hydrophilic solvents and/or solubilizers and/ or aqueous media, and one or more therapeutically active, hydrophobic agents. The compns. optionally further contain P-glycoprotein inhibitors, absorption enhancers or promoters, tight junction modulators, lipid membrane mobilizers, and antioxidants. For example, fenofibrate reverse micelle systems containing both hydrophilic and surfactant-miscible solubilizers were prepared containing PEG-8-caprylic/capric glycerides 6 g, PEG-4 lauryl ether 3.7 g, PEG 400 0.15 g, water 0.15 g and fenofibrate 1 g.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reverse micelle formulations comprising surfactants, hydrophilic phase, and lipophilic or hydrophobic compds.)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 23 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:346827 HCAPLUS Full-text
DOCUMENT NUMBER: 142:397743
TITLE: A solid dosage form comprising a fibrate and a statin
INVENTOR(S): Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005034908 | A2 | 20050421 | WO 2004-DK668 | 20041001 <-- |
| WO 2005034908 | A3 | 20050811 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004279661 | A1 | 20050421 | AU 2004-279661 | 20041001 <-- |
| CA 2541382 | A1 | 20050421 | CA 2004-2541382 | 20041001 <-- |

| | | | | | |
|---|---|---|---|---|---|
| EP 1680086 | A2 | 20060719 | EP 2004-762888 | | 20041001 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| BR 2004015121 | A | 20061128 | BR 2004-15121 | | 20041001 <-- |
| CN 1874758 | A | 20061206 | CN 2004-80031841 | | 20041001 <-- |
| JP 2007508249 | T | 20070405 | JP 2006-529649 | | 20041001 <-- |
| US 20050096390 | A1 | 20050505 | US 2004-988818 | | 20041115 <-- |
| US 20050096391 | A1 | 20050505 | US 2004-988829 | | 20041115 <-- |
| US 20060105050 | A1 | 20060518 | US 2004-988828 | | 20041115 <-- |
| US 20070009603 | A1 | 20070111 | US 2004-988917 | | 20041115 <-- |
| US 20060068015 | A1 | 20060330 | US 2005-513778 | | 20050714 <-- |
| MX 2006PA03813 | A | 20060614 | MX 2006-PA3813 | | 20060405 <-- |
| IN 2006CN01583 | A | 20070608 | IN 2006-CN1583 | | 20060509 <-- |
| US 20070026062 | A1 | 20070201 | US 2006-449918 | | 20060609 <-- |
| US 20070014846 | A1 | 20070118 | US 2006-456566 | | 20060711 <-- |
| PRIORITY APPLN. INFO.: | | | DK 2003-1503 | A | 20031010 <-- |
| | | | DK 2004-464 | A | 20040323 <-- |
| | | | DK 2004-1506 | A | 20041001 <-- |
| | | | WO 2004-DK668 | W | 20041001 <-- |
| | | | DK 2004-1761 | A | 20041115 <-- |
| | | | US 2004-988917 | A2 | 20041115 <-- |
| | | | DK 2005-196 | A | 20050209 <-- |
| | | | DK 2005-527 | A | 20050413 <-- |
| | | | DK 2005-534 | A | 20050413 <-- |
| | | | WO 2005-DK50001 | A2 | 20051003 <-- |
| | | | WO 2005-DK50004 | A2 | 20051003 <-- |
| | | | US 2006-787472P | P | 20060329 |
| | | | US 2006-790449P | P | 20060407 |

ED Entered STN: 22 Apr 2005

AB The present invention relates to pharmaceutical compns. in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors). The compns. are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e., the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration. Thus, tablets contained fenofibrate 160.09, PEG 208.12, Poloxamer-188 89.19, lactose 356.51, and Mg stearate 4.09 mg.

IT 49562-28-9, Fenofibrate
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage form comprising fibrate and statin)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




IT 42017-89-0, Fenofibric acid 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage form comprising fibrate and statin)

RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 24 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:220154 HCAPLUS Full-text

DOCUMENT NUMBER: 142:285226

TITLE: Multi-system therapy for diabetes, the metabolic syndrome and obesity

INVENTOR(S): Folli, Franco; Manfredi, Paolo; Gonzales, Gilbert

PATENT ASSIGNEE(S): Italy

SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20050054731 | A1 | 20050310 | US 2004-868227 | 20040615 <-- |
| CA 2538333 | A1 | 20050324 | CA 2004-2538333 | 20040826 <-- |
| WO 2005025673 | A1 | 20050324 | WO 2004-US27689 | 20040826 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1663395 A1 20060607 EP 2004-782221 20040826 <--
R: DE, ES, FR, GB, IT
IN 2006DN01141 A 20070810 IN 2006-DN1141 20060303 <--
PRIORITY APPLN. INFO.: US 2003-501226P P 20030908 <--
US 2004-868227 A 20040615 <--
WO 2004-US27689 W 20040826 <--

ED Entered STN: 13 Mar 2005

AB A multi-system therapy which is adapted to treat diabetes, metabolic syndrome and obesity includes a hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent. The composition can further include various vitamins and supplements such as vitamin B6, vitamin B12, arginine, a folate and other vitamins and minerals. Preferably, the hypoglycemic agent is a biguanide hypoglycemic agent without any addnl. hypoglycemic agent, making the composition suitable for treatment of individuals who are not hyperglycemic as well as those who are hyperglycemic. A capsule contained metformin 250, aspirin 12.5, simvastatin 3.5, lisinopril 1.66, folic acid 0.166, vitamin B6 8.33, and vitamin B12 0.166 mg. Efficacy of the composition was studied in mice.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multi-system therapy for diabetes, metabolic syndrome and obesity)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 25 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:219716 HCAPLUS Full-text

DOCUMENT NUMBER: 142:266843
TITLE: Osmotic delivery of drugs by solubility enhancement
INVENTOR(S): Kidane, Argaw; Ray, Shimul K.; Bhatt, Padmanabh P.; Bryan, Jones W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20050053653 | A1 | 20050310 | US 2003-655725 | 20030905 <-- |
| CA 2535060 | A1 | 20050317 | CA 2004-2535060 | 20040907 <-- |
| WO 2005023228 | A1 | 20050317 | WO 2004-US28875 | 20040907 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1660051 | A1 | 20060531 | EP 2004-783203 | 20040907 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| JP 2007504270 | T | 20070301 | JP 2006-526205 | 20040907 <-- |
| PRIORITY APPLN. INFO.: | | | US 2003-655725 A | 20030905 <-- |
| | | | WO 2004-US28875 W | 20040907 <-- |

ED Entered STN: 11 Mar 2005

AB The present invention is directed to the oral osmotic delivery of drugs that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load. Thus, a formulation contained 2.24, Xylitol CM90 44.45, Maltrin M150 (wet) 1.31, Maltrin M150 (dry) 45.09, meglumine 4.94, Mg stearate 0.98, and stearic acid 0.98%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osmotic delivery of drugs by solubility enhancement)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 26 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:965034 HCAPLUS Full-text
DOCUMENT NUMBER: 141:400958
TITLE: Drug formulations with methacrylic acid-methylacrylate-ethylacrylate-butylmethacrylate copolymer containing coating or matrix
INVENTOR(S): Petereit, Hans-Ulrich; Meier, Christian; Schultes, Klaus
PATENT ASSIGNEE(S): Roehm G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004096185 | A1 | 20041111 | WO 2004-EP2061 | 20040302 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10319458 | A1 | 20041118 | DE 2003-10319458 | 20030429 <-- |
| CA 2489064 | A1 | 20041111 | CA 2004-2489064 | 20040302 <-- |
| EP 1496870 | A1 | 20050119 | EP 2004-716230 | 20040302 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004003949 | A | 20050301 | BR 2004-3949 | 20040302 <-- |
| CN 1697649 | A | 20051116 | CN 2004-80000276 | 20040302 <-- |
| JP 2006524643 | T | 20061102 | JP 2006-504498 | 20040302 <-- |
| IN 2004CN02444 | A | 20070907 | IN 2004-CN2444 | 20040827 <-- |

US 20050152977 A1 20050714 US 2004-512860 20041115 <--
PRIORITY APPLN. INFO.: DE 2003-10319458 A 20030429 <--
WO 2004-EP2061 W 20040302 <--

ED Entered STN: 12 Nov 2004

AB The invention relates to a method for producing a coated dosage form or a dosage form in the form of a matrix containing an active substance. The dosage form is produced by processing a copolymer that contains a pharmaceutical active substance, an optional core and/or pharmaceutically conventional aggregates in a manner known per se by melting, injection-molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compaction to give a coated dosage form and/or to give a matrix containing an active substance. The method is characterized in that a copolymer is used that is composed of 20 to 33 % by weight of methacrylic acid, 5 to 30 % by weight of Me acrylate, 20 to 40 % by weight of Et acrylate, and more than 10 to 30 % by weight of Bu methacrylate and optionally 0 to 10 % by weight of addnl. vinylically copolymerizable monomers, with the proviso that the glass temperature of the copolymer is 55 to 70° according to ISO 11357-2, item 3.3.3. The invention also relates to the dosage form produced according to the invention, to the copolymer and to the use thereof. Thus a copolymer composed of (weight/weight%): methacrylic acid 30; methylacrylate 20; ethylacrylate 30 and butylmethacrylate 20 was used for the coating of quinidine sulfate; 469.7 g of the emulsion copolymerizate was mixed with 8.5 g polysorbate 80 (33% aqueous solution), 7.0 g glycerol monostearate and 268.7 g water. The coating suspension was applied in a spray-coating apparatus onto 200 g quinidine sulfate cores to result a 6.0 mg/cm2 coating.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug formulations with methacrylic acid-methylacrylate-ethylacrylate-butylmethacrylate copolymer containing coating or matrix)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 27 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:631261 HCAPLUS Full-text
DOCUMENT NUMBER: 141:162365
TITLE: Oral drug delivery systems with immediate dissolution and release that mask the unpleasant taste of the active substance and method for their preparation
INVENTOR(S): Petereit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas
PATENT ASSIGNEE(S): Roehm GmbH & Co. KG, Germany
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 10304403 | A1 | 20040805 | DE 2003-10304403 | 20030128 <-- |
| CA 2512738 | A1 | 20040812 | CA 2003-2512738 | 20031121 <-- |
| WO 2004066976 | A1 | 20040812 | WO 2003-EP13059 | 20031121 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003292061 | A1 | 20040823 | AU 2003-292061 | 20031121 <-- |
| EP 1587497 | A1 | 20051026 | EP 2003-767591 | 20031121 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003018049 | A | 20051220 | BR 2003-18049 | 20031121 <-- |
| JP 2006514660 | T | 20060511 | JP 2004-567296 | 20031121 <-- |
| US 20060051412 | A1 | 20060309 | US 2005-542283 | 20050715 <-- |
| MX 2005PA07643 | A | 20050930 | MX 2005-PA7643 | 20050718 <-- |
| IN 2005CN01698 | A | 20070622 | IN 2005-CN1698 | 20050726 <-- |

PRIORITY APPLN. INFO.: DE 2003-10304403 A 20030128 <--
WO 2003-EP13059 W 20031121 <--

ED Entered STN: 06 Aug 2004

AB The invention concerns oral drug delivery systems with immediate dissoln. and release that mask the unpleasant taste of the active substance and that are prepared by intense mixing of (a) an anionic drug; (b) a copolymer of acrylic acid or methacrylic acid C1-C4 esters with (meth)acrylate monomers containing tertiary amino-groups; (c) 5-50 weight/weight% rel. to (b) C12-C22 carboxylic acid; the mixture is melted, mixed, kneaded, cooled and ground to 200 μm size powder particles. The powder is embedded into a water-soluble matrix with other pharmaceutical auxiliary components in a way that the amount of emulsifiers with HLB ≥ 14 does not exceed 3 weight/weight% in relation to the copolymer. Mixing is performed in twin-screw extruders at 80-200 °C; pressing, casting, granulation or freeze drying is used for embedding. Thus a

composition was prepared from (g): Eudragit E PO 39.42; stearic acid 35.2; ibuprofen 16.9; talc 8.4. The mixture was kneaded at 100°C for 20 min; 1 g of the cooled composition was tasted; after 2 min no bitterness was sensed.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral drug delivery systems with immediate dissoln. and release to mask taste of active substance and method for their preparation)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 28 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:533962 HCAPLUS Full-text
DOCUMENT NUMBER: 141:82335
TITLE: Human glucagon-like-peptide-1 mimics and their antidiabetic effects
INVENTOR(S): Natarajan, Sesha Iyer; Mapelli, Claudio; Bastos, Margarita M.; Bernatowicz, Michael; Lee, Ving; Ewing, William R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U.S. Ser. No. 273,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

US 20040127423 A1 20040701 US 2003-419399 20030421 <--
US 7238671 B2 20070703
US 20030195157 A1 20031016 US 2002-273975 20021018 <--
US 7238670 B2 20070703
WO 2004094461 A2 20041104 WO 2004-US12374 20040421 <--
WO 2004094461 A3 20050915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1615653 A2 20060118 EP 2004-760098 20040421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
US 20070287670 A1 20071213 US 2007-740031 20070425 <--
PRIORITY APPLN. INFO.: US 2001-342015P P 20011018 <--
US 2002-273975 A2 20021018 <--
US 2003-419399 A 20030421 <--
WO 2004-US12374 W 20040421 <--

ED Entered STN: 02 Jul 2004

AB The invention discloses human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the invention provides novel, chemical modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

IT 49562-28-9, Fenofibrate 134523-00-5, Ator-vastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human glucagon-like-peptide-1 mimics and their antidiabetic effects)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 122 THERE ARE 122 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 29 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:490278 HCAPLUS Full-text
DOCUMENT NUMBER: 141:42922
TITLE: Hydrophobic active agent compositions and methods
INVENTOR(S): Chen, Feng-Jing; Gutke, Kathryn; Venkateshwaran, Srinivasan; Patel, Mahesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20040115287 | A1 | 20040617 | US 2002-322344 | 20021217 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-322344 | 20021217 <-- |

ED Entered STN: 17 Jun 2004
AB Compns. and methods for providing hydrophobic active agents in a bioavailable form, including cyclosporine are disclosed. In one aspect of the invention, a cyclosporine composition may be formulated that produces an aqueous dispersion containing cyclosporine in both dissolved and undissolved forms. In another aspect, the undissolved form of cyclosporine may be indicated by retention of cyclosporine particles on a 0.2 μm membrane upon filtration of the aqueous dispersion therewith. In another aspect, the undissolved form of cyclosporine may be indicated by formation of a pellet upon centrifugation of the aqueous dispersion at about 12 K+G for about 10 min. A claimed pharmaceutical composition comprises: a therapeutically effective amount of cyclosporine; a solubilizer of ethanol; and a stabilizer of a polyethoxylated castor oil and a polyethoxylated hydrogenated castor oil, in an amount sufficient to provide a ratio of stabilizer to cyclosporine of at least about 5:1, wherein upon contact with an aqueous medium, the composition forms a bioavailable dispersion of dissolved cyclosporine and particles containing undissolved cyclosporine, with at least about 35 % of the cyclosporine being dissolved.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical dispersions containing hydrophobic drug and solubilizer and stabilizer)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 30 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:490267 HCAPLUS Full-text

DOCUMENT NUMBER: 141:42919

TITLE: Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same

INVENTOR(S): Li, Wenji; Alosio, Edward; Dema-Ala, Bricini Faith; Nguyen, Amy

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20040115226 | A1 | 20040617 | US 2002-317657 | 20021212 <-- |
| WO 2004054540 | A2 | 20040701 | WO 2003-US38979 | 20031209 <-- |
| WO 2004054540 | A3 | 20040930 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU 2003300833 | A1 | 20040709 | AU 2003-300833 | | 20031209 <-- |
| JP 2006511536 | T | 20060406 | JP 2004-560372 | | 20031209 <-- |
| US 20060263397 | A1 | 20061123 | US 2006-494131 | | 20060727 <-- |
| US 20070009559 | A1 | 20070111 | US 2006-494129 | | 20060727 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-317657 | A | 20021212 <-- |
| | | | WO 2003-US38979 | W | 20031209 <-- |

ED Entered STN: 17 Jun 2004

AB Disclosed is a free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1-30 % of the drug, 5-60 % of a surfactant, 10-40 % of water; 1-20 % of unsatd. fatty acid ester, 0-50 % water miscible pharmaceutically acceptable polyol and 1-10 % phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixt. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form. A gel composition containing polyoxyethylene sorbitan monooleate 35, propylene glycol 25, Et linoleate 8, simvastatin 4, and 5 % lecithin aqueous solution q.s. to 100 % was formulated. Colloidal silicon dioxide 30 parts was granulated with the obtained gel 70 parts. The granules was dried to provide a free-flowing powder. When this powder was exposed to a gastric medium of pH 1.2, 67 % of the drug simvastatin dissolved within 10 min.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(free-flowing solid formulations with improved bio-availability of poorly water soluble drugs obtained from gel compns. containing surfactants,
fatty acid esters, polyols, and phospholipids)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 31 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:287775 HCAPLUS Full-text
DOCUMENT NUMBER: 140:309387
TITLE: Oral pharmaceutical compositions of fenofibrate having high bioavailability
INVENTOR(S): Miriyala, Gowri Shankar; Singla, Ajay Kumar; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India; Roy, Sunilendu Bhushan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004028506 | A1 | 20040408 | WO 2003-IB4162 | 20030924 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| IN 2002DE00961 | A | 20050121 | IN 2002-DE961 | 20020924 <-- |
| AU 2003263480 | A1 | 20040419 | AU 2003-263480 | 20030924 <-- |
| EP 1553928 | A1 | 20050720 | EP 2003-798327 | 20030924 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| IN 2005DN01508 | A | 20071130 | IN 2005-DN1508 | 20050415 <-- |
| PRIORITY APPLN. INFO.: | | | IN 2002-DE961 A | 20020924 <-- |
| | | | WO 2003-IB4162 W | 20030924 <-- |

ED Entered STN: 08 Apr 2004
AB The present invention relates to oral pharmaceutical compns. of fenofibrate having high bioavailability with improved dissoln. and methods for providing the pharmaceutical compns. The oral pharmaceutical composition of fenofibrate include an inert hydro-insol. carrier having one or more one layers that include fenofibrate in a micronized form, one or more hydrophilic polymers, and one or more surfactants. The composition may have a dissoln. profile of at least about 10% in about 5 min, about 20% in about 10 min, about 50% in about 20 min and about 75% in about 30 min, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia in a dissoln. medium constituted by water with 2% by weight of Polysorbate 80 or with 0.025M sodium lauryl sulfate.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral pharmaceutical compns. of fenofibrate having high bioavailability)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl

ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 32 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1007596 HCAPLUS Full-text
DOCUMENT NUMBER: 140:65183
TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
INVENTOR(S): Chen, Feng-Jing; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Pat. Appl. 2002 32,171.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030235595 | A1 | 20031225 | US 2003-397969 | 20030325 <-- |
| US 6267985 | B1 | 20010731 | US 1999-345615 | 19990630 <-- |
| US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 <-- |
| US 20010024658 | A1 | 20010927 | US 2000-751968 | 20001229 <-- |
| US 6458383 | B2 | 20021001 | | |
| US 20020032171 | A1 | 20020314 | US 2001-877541 | 20010608 <-- |
| US 6761903 | B2 | 20040713 | | |
| WO 2004087052 | A2 | 20041014 | WO 2004-US9120 | 20040325 <-- |

WO 2004087052 A3 20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1999-345615 | A2 | 19990630 <-- |
| US 1999-375636 | A2 | 19990817 <-- |
| US 2000-751968 | A2 | 20001229 <-- |
| US 2001-877541 | A2 | 20010608 <-- |
| WO 2000-US18807 | A | 20000710 <-- |
| US 2003-397969 | A | 20030325 <-- |

ED Entered STN: 28 Dec 2003

AB The present invention relates to oral pharmaceutical compns. and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compns. of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compns. provided.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral composition containing triglyceride and surfactants for improved delivery
of hydrophobic drugs)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 42017-89-0, Fenofibric acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(plasma concentration of; oral composition containing triglyceride and surfactants for
improved delivery of hydrophobic drugs)
RN 42017-89-0 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



L55 ANSWER 33 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1007351 HCAPLUS Full-text
DOCUMENT NUMBER: 140:65181
TITLE: Solid pharmaceutical composition containing a lipophilic active ingredient and process for its preparation
INVENTOR(S): Abou Chacra, Vernet Marie Line; Zakarian, Noel; Toselli, Dominique; Gimet, Rene; Laruelle, Claude
PATENT ASSIGNEE(S): CLL Pharma, Fr.
SOURCE: Fr. Demande, 36 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| FR 2841138 | A1 | 20031226 | FR 2002-7831 | 20020625 <-- |
| FR 2841138 | B1 | 20050225 | | |
| CA 2490341 | A1 | 20031231 | CA 2003-2490341 | 20030624 <-- |
| WO 2004000279 | A1 | 20031231 | WO 2003-FR1933 | 20030624 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

```
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003260621         A1    20040106    AU 2003-260621          20030624 <--
     EP 1521574            A1    20050413    EP 2003-760779          20030624 <--
     EP 1521574            B1    20070307
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005533802         T     20051110    JP 2004-514981          20030624 <--
     AT 355829             T     20070315    AT 2003-760779          20030624 <--
     ES 2283821            T3    20071101    ES 2003-760779          20030624 <--
     ZA 2005000716         A     20060927    ZA 2005-716             20050125 <--
     US 20080095838        A1    20080424    US 2005-519166          20051026 <--
PRIORITY APPLN. INFO.:                       FR 2002-7831         A  20020625 <--
                                             WO 2003-FR1933       W  20030624 <--
ED   Entered STN:  28 Dec 2003
AB    A solid oral pharmaceutical composition, comprises a lipophilic active
      ingredient, a surfactant, a cationic polymer insol. in water at pH equal to or
      higher than 5, and one mineral or organic acid.  Preparation of tablets
      containing 195 mg fenofibrate are described.
IT   49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (solid pharmaceutical composition containing lipophilic active ingredient
and
        process for its preparation)
RN   49562-28-9  HCAPLUS
CN   Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
     ester  (CA INDEX NAME)
```




```
RN   134523-00-5  HCAPLUS
CN   1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-
     (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
     (CA INDEX NAME)

Absolute stereochemistry.
```




```
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L55 ANSWER 34 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:757020 HCAPLUS Full-text
DOCUMENT NUMBER: 139:281229
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of U.S. Ser. No. 800,593.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030180352 | A1 | 20030925 | US 2002-159601 | 20020530 <-- |
| US 6248363 | B1 | 20010619 | US 1999-447690 | 19991123 <-- |
| US 20030064097 | A1 | 20030403 | US 2001-800593 | 20010306 <-- |
| US 6569463 | B2 | 20030527 | | |

PRIORITY APPLN. INFO.: US 1999-447690 A3 19991123 <--
US 2001-800593 A2 20010306 <--

ED Entered STN: 26 Sep 2003

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. For example, beads were prepared containing omeprazole 8.8%, PEG-150 monostearate 27.8%, PEG-40 monostearate 13.9%, Maisine 35-1 4.6%, magnesium carbonate 0.9%, and nonpareil seed (30/35 mesh) 44.1%. The beads were further coated with an enteric coating layer by spraying a Eudragit L100 solution

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of therapeutic agents)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 35 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:696722 HCAPLUS Full-text
DOCUMENT NUMBER: 139:219350
TITLE: Pharmaceutical dosage forms coated with and acrylic copolymers
INVENTOR(S): Petereit, Hans-Ulrich; Suefke, Thomas; Meier, Christian; Schnabel, Michael; Blesing, Ingrid; Grimm, Stefan
PATENT ASSIGNEE(S): Roehm G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003072087 | A1 | 20030904 | WO 2003-EP934 | 20030130 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10208335 | A1 | 20030904 | DE 2002-10208335 | 20020227 <-- |
| CA 2476972 | A1 | 20030904 | CA 2003-2476972 | 20030130 <-- |
| AU 2003218641 | A1 | 20030909 | AU 2003-218641 | 20030130 <-- |
| EP 1478352 | A1 | 20041124 | EP 2003-711870 | 20030130 <-- |
| EP 1478352 | B1 | 20060816 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003008006 | A | 20050104 | BR 2003-8006 | 20030130 <-- |
| JP 2005526546 | T | 20050908 | JP 2003-570833 | 20030130 <-- |
| AT 336232 | T | 20060915 | AT 2003-711870 | 20030130 <-- |
| ES 2272955 | T3 | 20070501 | ES 2003-711870 | 20030130 <-- |
| US 20050079216 | A1 | 20050414 | US 2004-502648 | 20040803 <-- |
| IN 2004CN01861 | A | 20060623 | IN 2004-CN1861 | 20040820 <-- |

| | | | | | |
|---|---|---|---|---|---|
| MX 2004PA08344 | A | 20041126 | MX 2004-PA8344 | | 20040827 <-- |
| KR 784657 | B1 | 20071212 | KR 2004-713492 | | 20040827 <-- |
| MX 2004PA10956 | A | 20050125 | MX 2004-PA10956 | | 20041105 <-- |
| PRIORITY APPLN. INFO.: | | | DE 2002-10208335 | A | 20020227 <-- |
| | | | WO 2003-EP934 | W | 20030130 <-- |
| | | | DE 2003-10319458 | A | 20030429 <-- |

ED Entered STN: 05 Sep 2003

AB The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 weight % methacrylic acid, 20 to 69 weight % methylacrylate and 0 to 40 weight % ethylacrylate and, optionally, of 0 to 10 weight % of addnl. vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof. Thus a copolymer was prepared using the monomers: Me acrylate 40; Et acrylate 30; methacrylic acid 30. An emulsion polymerizate containing 30% of the copolymer was mixed with 0.85% sodium lauryl sulfate (in relation to the copolymer); the fluid was dried to a film; the film was soluble in an artificial intestinal juice at pH 6.8.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical dosage forms coated with and acrylic copolymers)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 36 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:633275 HCAPLUS Full-text
DOCUMENT NUMBER: 139:169333
TITLE: Novel anticholesterol compositions and method for using same
INVENTOR(S): Dudley, Robert; Liao, Shutsung; Song, Ching
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030153541 | A1 | 20030814 | US 2002-174934 | 20020619 <-- |
| WO 9922728 | A1 | 19990514 | WO 1998-US23041 | 19981030 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6576660 | B1 | 20030610 | US 2000-530443 | 20000428 <-- |
| US 6645955 | B1 | 20031111 | US 2000-560236 | 20000428 <-- |
| ZA 2001009793 | A | 20030228 | ZA 2001-9793 | 20011128 <-- |
| CA 2438221 | A1 | 20020815 | CA 2002-2438221 | 20020207 <-- |
| AU 2002238093 | A1 | 20020819 | AU 2002-238093 | 20020207 <-- |
| EP 1385868 | A2 | 20040204 | EP 2002-704407 | 20020207 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2005508281 | T | 20050331 | JP 2002-562310 | 20020207 <-- |
| US 20020107233 | A1 | 20020808 | US 2002-72128 | 20020208 <-- |
| US 20020193357 | A1 | 20021219 | US 2002-137695 | 20020502 <-- |
| US 7012069 | B2 | 20060314 | | |
| CA 2489702 | A1 | 20031231 | CA 2003-2489702 | 20030619 <-- |
| WO 2004001002 | A2 | 20031231 | WO 2003-US19515 | 20030619 <-- |
| WO 2004001002 | A3 | 20040506 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, | | | | |

```
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003245605        A1    20040106    AU 2003-245605         20030619 <--
    EP 1534298           A2    20050601    EP 2003-739234         20030619 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    JP 2005533810        T     20051110    JP 2004-516031         20030619 <--
PRIORITY APPLN. INFO.:                     US 1997-63770P      P  19971031 <--
                                           WO 1998-US23041     W  19981030 <--
                                           US 1999-131728P     P  19990430 <--
                                           US 2000-530443      A2 20000428 <--
                                           US 2000-560236      A2 20000428 <--
                                           US 2001-267493P     P  20010208 <--
                                           US 2001-288643P     P  20010503 <--
                                           US 2001-348020P     P  20011108 <--
                                           US 2002-72128       A2 20020208 <--
                                           US 2002-137695      A2 20020502 <--
                                           US 2000-191864P     P  20000324 <--
                                           WO 2002-US3826      W  20020207 <--
                                           US 2002-174934      A  20020619 <--
                                           WO 2003-US19515     W  20030619 <--
OTHER SOURCE(S):         MARPAT 139:169333
ED   Entered STN:  15 Aug 2003
AB   Disclosed are compns., methods, combinations, and kits for treating a disorder
     related to elevated serum cholesterol concentration, for example,
     atherosclerosis, elevated LDL plasma levels, low HDL plasma levels,
     hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia,
     cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The
     compns., methods, combinations, and kits of the present invention are
     pharmaceutical compns. comprising at least two of an LXR receptor modulator, a
     therapeutically effective amount of a catechin, and/or a therapeutically
     effective amount of a lipid regulating agent, such as a HMG-CoA reductase
     inhibitor, a fibric acid derivative, niacin, a bile-acid sequestrant, an
     absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone
     compound, and an unsatd. omega-3 fatty acid.
IT   49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (anticholesterol compns. containing LXR modulators and lipid regulating
        agents)
RN   49562-28-9  HCAPLUS
CN   Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
     ester  (CA INDEX NAME)
```




```
RN   134523-00-5  HCAPLUS
```

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




L55 ANSWER 37 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:492691 HCAPLUS Full-text
DOCUMENT NUMBER: 139:47151
TITLE: Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
INVENTOR(S): Davis, Harry R.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20030119757 | A1 | 20030626 | US 2002-247032 | 20020919 <-- |
| US 20030105028 | A1 | 20030605 | US 2002-166942 | 20020611 <-- |
| US 6982251 | B2 | 20060103 | | |
| AU 2007201970 | A1 | 20070524 | AU 2007-201970 | 20070503 |
| AU 2007201970 | B2 | 20080417 | | |
| AU 2008201609 | A1 | 20080501 | AU 2008-201609 | 20080410 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2001-323937P | P | 20010921 <-- |
| US 2002-166942 | A2 | 20020611 <-- |
| US 2000-256875P | P | 20001220 <-- |
| US 2001-23295 | A2 | 20011217 <-- |
| AU 2006-202618 | A3 | 20060620 |
| AU 2007-201970 | A3 | 20070503 |

OTHER SOURCE(S): MARPAT 139:47151
ED Entered STN: 29 Jun 2003
AB The present invention provides methods for treating or preventing vascular inflammation or for reducing blood levels of C-reactive protein by administering at least one sterol absorption inhibitor and/or at least one 5α-stanol absorption inhibitor. A tablet formulation for a sterol of 5α-stanol absorption inhibitor is presented as well as preparation of ezetimibe. Patients with primary hypercholesterolemia treated with ezetimibe and simvastatin showed significant reduction of C-reactive protein levels.
IT 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HMG-CoA reductase inhibitor; sterol or 5α-stanol absorption inhibitor for reducing blood levels of C-reactive protein and treating or preventing vascular inflammation)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




IT 49562-28-9, Fenofibrate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(further administering peroxisome proliferator-activated receptor activating; sterol or 5α-stanol absorption inhibitor for reducing blood levels of C-reactive protein and treating or preventing vascular inflammation)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




L55 ANSWER 38 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:334829 HCAPLUS Full-text

DOCUMENT NUMBER: 138:343889

TITLE: Novel pharmaceutical compounds containing drugs bound to polypeptides

INVENTOR(S): Picariello, Thomas

PATENT ASSIGNEE(S): New River Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 4662 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 27

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| WO 2003034980 | A2 | 20030501 | WO 2001-US43089 | 20011114 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2428971 | A1 | 20030501 | CA 2001-2428971 | 20011114 <-- |
| AU 2001298033 | A1 | 20030506 | AU 2001-298033 | 20011114 <-- |
| AU 2001298033 | B2 | 20070809 | | |
| EP 1401374 | A1 | 20040331 | EP 2001-274606 | 20011114 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2006516948 | T | 20060713 | JP 2003-537549 | 20011114 <-- |
| US 20040063628 | A1 | 20040401 | US 2002-156527 | 20020529 <-- |
| US 7060708 | B2 | 20060613 | | |
| US 20070232529 | A1 | 20071004 | US 2004-923088 | 20040823 <-- |
| US 7427600 | B2 | 20080923 | | |
| US 20070060500 | A1 | 20070315 | US 2006-392878 | 20060330 <-- |
| US 20080086016 | A1 | 20080410 | US 2007-745019 | 20070507 <-- |
| AU 2007203485 | A1 | 20070816 | AU 2007-203485 | 20070726 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-247622P | P 20001114 <-- |
| | | | US 1999-265415 | B2 19990310 <-- |
| | | | US 1999-411238 | B2 19991004 <-- |
| | | | WO 2000-US5693 | A 20000306 <-- |
| | | | US 2000-642820 | A2 20000822 <-- |
| | | | US 2000-247556P | P 20001114 <-- |
| | | | US 2000-247558P | P 20001114 <-- |
| | | | US 2000-247559P | P 20001114 <-- |
| | | | US 2000-247560P | P 20001114 <-- |
| | | | US 2000-247561P | P 20001114 <-- |
| | | | US 2000-247594P | P 20001114 <-- |
| | | | US 2000-247595P | P 20001114 <-- |
| | | | US 2000-247606P | P 20001114 <-- |
| | | | US 2000-247607P | P 20001114 <-- |
| | | | US 2000-247608P | P 20001114 <-- |
| | | | US 2000-247610P | P 20001114 <-- |
| | | | US 2000-247613P | P 20001114 <-- |
| | | | US 2000-247614P | P 20001114 <-- |
| | | | US 2000-247615P | P 20001114 <-- |
| | | | US 2000-247616P | P 20001114 <-- |
| | | | US 2000-247617P | P 20001114 <-- |
| | | | US 2000-247620P | P 20001114 <-- |
| | | | US 2000-247621P | P 20001114 <-- |
| | | | US 2000-247625P | P 20001114 <-- |
| | | | US 2000-247626P | P 20001114 <-- |
| | | | US 2000-247627P | P 20001114 <-- |
| | | | US 2000-247628P | P 20001114 <-- |
| | | | US 2000-247629P | P 20001114 <-- |
| | | | US 2000-247630P | P 20001114 <-- |
| | | | US 2000-247631P | P 20001114 <-- |
| | | | US 2000-247632P | P 20001114 <-- |
| | | | US 2000-247633P | P 20001114 <-- |
| | | | US 2000-247634P | P 20001114 <-- |
| | | | US 2000-247635P | P 20001114 <-- |

US 2000-247684P P 20001114 <--
US 2000-247698P P 20001114 <--
US 2000-247699P P 20001114 <--
US 2000-247700P P 20001114 <--
US 2000-247701P P 20001114 <--
US 2000-247702P P 20001114 <--
US 2000-247798P P 20001114 <--
US 2000-247799P P 20001114 <--
US 2000-247800P P 20001114 <--
US 2000-247801P P 20001114 <--
US 2000-247802P P 20001114 <--
US 2000-247803P P 20001114 <--
US 2000-247804P P 20001114 <--
US 2000-247805P P 20001114 <--
US 2000-247807P P 20001114 <--
US 2000-247832P P 20001114 <--
US 2000-247833P P 20001114 <--
US 2000-247926P P 20001114 <--
US 2000-247927P P 20001114 <--
US 2000-247930P P 20001114 <--
US 2000-274622P P 20001114 <--
US 2000-248528P P 20001116 <--
US 2000-248529P P 20001116 <--
US 2000-248530P P 20001116 <--
US 2000-248531P P 20001116 <--
US 2000-248532P P 20001116 <--
US 2000-248533P P 20001116 <--
US 2000-248535P P 20001116 <--
US 2000-248536P P 20001116 <--
US 2000-248537P P 20001116 <--
US 2000-248538P P 20001116 <--
US 2000-248539P P 20001116 <--
US 2000-248540P P 20001116 <--
US 2000-248620P P 20001116 <--
US 2000-248662P P 20001116 <--
US 2000-248663P P 20001116 <--
US 2000-248685P P 20001116 <--
US 2000-248713P P 20001116 <--
US 2000-248714P P 20001116 <--
US 2000-248715P P 20001116 <--
US 2000-248716P P 20001116 <--
US 2000-248717P P 20001116 <--
US 2000-248721P P 20001116 <--
US 2000-248722P P 20001116 <--
US 2000-248723P P 20001116 <--
US 2000-248724P P 20001116 <--
US 2000-248725P P 20001116 <--
US 2000-248726P P 20001116 <--
US 2000-248727P P 20001116 <--
US 2000-248728P P 20001116 <--
US 2000-248729P P 20001116 <--
US 2000-248730P P 20001116 <--
US 2000-248731P P 20001116 <--
US 2000-248732P P 20001116 <--
US 2000-248733P P 20001116 <--
US 2000-248737P P 20001116 <--
US 2000-248738P P 20001116 <--
US 2000-248748P P 20001116 <--
US 2000-248764P P 20001116 <--
US 2000-248765P P 20001116 <--

| | | | |
|---|---|---|---|
| US | 2000-248767P | P | 20001116 <-- |
| US | 2000-248768P | P | 20001116 <-- |
| US | 2000-248769P | P | 20001116 <-- |
| US | 2000-248770P | P | 20001116 <-- |
| US | 2000-248771P | P | 20001116 <-- |
| US | 2000-248772P | P | 20001116 <-- |
| US | 2000-248774P | P | 20001116 <-- |
| US | 2000-248776P | P | 20001116 <-- |
| US | 2000-248777P | P | 20001116 <-- |
| US | 2000-248778P | P | 20001116 <-- |
| US | 2000-248779P | P | 20001116 <-- |
| US | 2000-248782P | P | 20001116 <-- |
| US | 2000-248783P | P | 20001116 <-- |
| US | 2000-248787P | P | 20001116 <-- |
| US | 2000-248794P | P | 20001116 <-- |
| US | 2000-248795P | P | 20001116 <-- |
| US | 2000-248796P | P | 20001116 <-- |
| US | 2000-248797P | P | 20001116 <-- |
| US | 2000-248833P | P | 20001116 <-- |
| US | 2001-933708 | A2 | 20010822 <-- |
| US | 2001-986426 | A2 | 20011108 <-- |
| AU | 2001-298033 | A3 | 20011114 <-- |
| US | 2001-987458 | B2 | 20011114 <-- |
| WO | 2001-US43089 | W | 20011114 <-- |
| US | 2001-988034 | B2 | 20011116 <-- |
| US | 2001-988071 | B2 | 20011116 <-- |
| WO | 2001-US43115 | B2 | 20011116 <-- |
| WO | 2001-US43117 | B2 | 20011116 <-- |
| US | 2002-358381P | P | 20020222 <-- |
| US | 2002-366258P | P | 20020322 <-- |
| US | 2002-156527 | A2 | 20020529 <-- |
| WO | 2003-US5524 | A2 | 20030224 <-- |
| US | 2003-507012P | P | 20030930 <-- |
| US | 2003-727565 | A2 | 20031205 <-- |
| US | 2004-567800P | P | 20040505 <-- |
| US | 2004-567802P | P | 20040505 <-- |
| US | 2004-568011P | P | 20040505 <-- |
| US | 2004-857619 | A3 | 20040601 <-- |
| US | 2004-923088 | A2 | 20040823 <-- |
| WO | 2004-US32131 | A2 | 20040930 <-- |

ED Entered STN: 02 May 2003

AB Compns. comprising polypeptides and drugs covalently attached to the polypeptide are disclosed. Also provided is a method for delivery of these drugs to a patient comprising administering to the patient a composition comprising a polypeptide and a drug covalently attached to the polypeptide. Also provided is a method for protecting drugs from degradation comprising covalently attaching them to a polypeptide. Also provided is a method for controlling release of drugs from a composition comprising covalently attaching them to the polypeptide.

IT 49562-28-9DP, Fenofibrate, protein conjugates
134523-00-5DP, Atorvastatin, protein conjugates
RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel pharmaceutical compds. containing drugs bound to polypeptides)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 39 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:133112 HCAPLUS Full-text
DOCUMENT NUMBER: 138:175886
TITLE: Oral pharmaceutical composition containing a combination of PPARα and HMG-CoA reductase inhibitor
INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe; Sereno, Antonio
PATENT ASSIGNEE(S): Galephar M/F, Belg.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003013608 | A1 | 20030220 | WO 2002-BE135 | 20020807 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2003013607 | A1 | 20030220 | WO 2001-BE147 | 20010907 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
            UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2456732          A1    20030220    CA 2002-2456732        20020807 <--
    AU 2002331468       A1    20030224    AU 2002-331468         20020807 <--
    EP 1414496          A1    20040506    EP 2002-766983         20020807 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
    US 20050032878      A1    20050210    US 2004-486219         20040908 <--
    US 20070092567      A1    20070426    US 2006-347822         20060206 <--
PRIORITY APPLN. INFO.:                    WO 2001-BE133       W  20010807 <--
                                          WO 2001-BE147       W  20010907 <--
                                          WO 2002-BE135       W  20020807 <--
                                          WO 2003-BE133       A2 20030806 <--
                                          US 2004-486219      A2 20040908 <--

ED   Entered STN:  21 Feb 2003
AB   Disclosed is an oral pharmaceutical composition containing, in the same
     pharmaceutical form, effective amts. of a HMG-CoA reductase inhibitor
     derivative and of peroxisome proliferator activated receptor-α (PPARα),
     especially fenofibrate.  Also described is the use of some inactive
     ingredients which allow to improve the dissoln. and/or bioavailability of the
     drugs from the said composition  A capsule containing simvastatin 20,
     fenofibrate 200, Gelucire 44/14 350, vitamin E TPGS 20, polyethylene glycol
     6000 30, buthylhydroxyanisol 0.08 mg was prepared
IT   49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (oral pharmaceutical composition containing PPARα, HMG-CoA reductase
        inhibitor, glyceride derivs., and other excipients)
RN   49562-28-9  HCAPLUS
CN   Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
     ester  (CA INDEX NAME)
```




```
RN   134523-00-5  HCAPLUS
CN   1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-
     (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
     (CA INDEX NAME)

Absolute stereochemistry.
```



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 40 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:675771 HCAPLUS Full-text
DOCUMENT NUMBER: 137:206561
TITLE: Controlled-release pharmaceuticals containing fatty esters and a cellulose and nonionic surfactant
INVENTOR(S): Gutierrez-Rocca, Jose; Dunne, Josephine; Rios, Saul A.
PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002067852 | A2 | 20020906 | WO 2002-US1879 | 20020122 <-- |
| WO 2002067852 | A3 | 20030220 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20020160041 | A1 | 20021031 | US 2001-790239 | 20010221 <-- |
| US 6524615 | B2 | 20030225 | | |
| AU 2002248377 | A1 | 20020912 | AU 2002-248377 | 20020122 <-- |
| US 20030118639 | A1 | 20030626 | US 2002-212484 | 20020805 <-- |
| US 6596308 | B2 | 20030722 | | |
| US 20030165562 | A1 | 20030904 | US 2003-337233 | 20030106 <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-790239 A | 20010221 <-- |
| | | | WO 2002-US1879 W | 20020122 <-- |

ED Entered STN: 08 Sep 2002
AB A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation containing a water-insol. drug, a high melting fatty ester, a low-viscosity oil, a cellulose polymer, and a nonionic surfactant. Thus, a controlled-release capsule formulation contained nifedipine 20.0, Compritol-888 25.0, Methocel K-100 3.0, Labrasol 51.0, and Polysorbate-80 2.0 mg.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release pharmaceuticals containing fatty esters and cellulose

and nonionic surfactant)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 41 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:256815 HCAPLUS Full-text
DOCUMENT NUMBER: 136:284466
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Patel, Jitendra P.; Sanzgiri, Yeshwant D.; Lipari, John M.; Reinland, Thomas L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 20020040046 | A1 | 20020404 | US 2000-524113 | | 20000313 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-127136P | P | 19990331 <-- |

ED Entered STN: 05 Apr 2002
AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium. SR soybean oil (24.33 g) was added to a beaker and fenofibrate (0.67 g) was dissolved in it by stirring. Sorbitan monooleate (2.5 g) was added to the beaker and mixed until uniform.

Polysorbate 80 (0.5 g) was then added and mixed until uniform. Finally water (72 g) was added slowly with constant mixing until a uniform emulsion resulted. Pharmacokinetics of 67 mg/day fenofibrate was compared with Lipanthyl 67M in fasted dogs.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel formulations comprising lipid-regulating agents)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 42 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:240538 HCAPLUS Full-text
DOCUMENT NUMBER: 136:268166
TITLE: Spray drying process for preparation of fenofibrate compositions
INVENTOR(S): Pace, Gary; Mishra, Awadhesh K.; Snow, Robert A.; Parikh, Indu; Guivarc'h, Pol-Henri
PATENT ASSIGNEE(S): RTP Pharma Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024169 | A1 | 20020328 | WO 2001-US12746 | 20010420 <-- |

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
            RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2423335           A1    20020328    CA 2001-2423335        20010420 <--
    AU 2001062945        A     20020402    AU 2001-62945          20010420 <--
    US 20020056206       A1    20020516    US 2001-838593         20010420 <--
    US 6696084           B2    20040224
    CA 2440355           A1    20020906    CA 2001-2440355        20010420 <--
    WO 2002067901        A1    20020906    WO 2001-US12747        20010420 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
            RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 2001259099        A1    20020912    AU 2001-259099         20010420 <--
    AU 2001259099        B2    20051222
    US 20020161032       A1    20021031    US 2001-838583         20010420 <--
    US 6534088           B2    20030318
    EP 1322289           A1    20030702    EP 2001-937182         20010420 <--
    EP 1322289           B1    20070725
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    EP 1361867           A1    20031119    EP 2001-932584         20010420 <--
    EP 1361867           B1    20070321
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    CN 1505502           A     20040616    CN 2001-823164         20010420 <--
    CN 1273112           C     20060906
    JP 2004523552        T     20040805    JP 2002-567269         20010420 <--
    NZ 525306            A     20041126    NZ 2001-525306         20010420 <--
    NZ 527408            A     20050429    NZ 2001-527408         20010420 <--
    AU 2001262945        B2    20060202    AU 2001-262945         20010420 <--
    AT 357216            T     20070415    AT 2001-932584         20010420 <--
    AT 367802            T     20070815    AT 2001-937182         20010420 <--
    TW 288000            B     20071011    TW 2001-90109551       20010420 <--
    ES 2284646           T3    20071116    ES 2001-932584         20010420 <--
    US 20040086571       A1    20040506    US 2003-388597         20030317 <--
    HK 1061357           A1    20071102    HK 2004-102918         20040426 <--
    AU 2007201953        A1    20070524    AU 2007-201953         20070501 <--
PRIORITY APPLN. INFO.:                       US 2000-234186P     P  20000920 <--
                                             US 2000-241761P     P  20001020 <--
                                             US 2001-270157P     P  20010222 <--
                                             AU 2001-55515       T0 20010420 <--
                                             US 2001-838583      A3 20010420 <--
                                             WO 2001-US12746     W  20010420 <--
                                             WO 2001-US12747     W  20010420 <--
ED   Entered STN:  28 Mar 2002
AB   The present invention relates to a novel spray drying process for the
     preparation of pharmaceutical compns. containing small particles of
     phospholipid-stabilized fenofibrate.  This invention also relates to spray
```

dried powdered compns. prepared according to this process and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compns. The powdered compns. and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally. An admixt. of 3% Lipoid E80 as the surfactant and 10% fenofibrate is homogeneously dispersed in pH 8.0 10 mM aqueous phosphate buffer by using a high-shear mixer for 30 min. Mannitol (10%) is then added and the admixt. is heated to 95° during continuous high shear mixing. The heated suspension is then homogenized for 10 batch volume cycles or passes by using a microfluidizer to form a heated homogenate containing the drug. After 10 passes, the heated homogenate is then spray dried to produce a dried powder containing Lipoid E80-stabilized microparticles of fenofibrate in mannitol.

IT 49562-28-9, Fenofibrate
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spray drying for preparation of fenofibrate compns.)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




IT 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spray drying for preparation of fenofibrate compns.)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 43 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:489854 HCAPLUS Full-text
DOCUMENT NUMBER: 135:97449

TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20010006658 | A1 | 20010705 | US 1999-283083 | 19990331 <-- |
| US 6719999 | B2 | 20040413 | | |
| PRIORITY APPLN. INFO.: | | | US 1999-283083 | 19990331 <-- |

ED Entered STN: 06 Jul 2001

AB The present invention is directed to a formulation comprising a lipid-regulating agent, e.g., fenofibrate, pravastatin and atorvastatin, dissolved in one or more non-aqueous and/or water-miscible solvents, e.g., ethanol, or optionally, in a premix of one or more solvents and one or more surfactants, such as, Labrafac Lipophile WL 1349, Lauroglycol FCC, Labrafil M 1944, Span 80, sorbitan oleate, etc. A hypolipemic liquid composition is filled into capsules. For example, pravastatin (5.0 g) was mixed with di-Me isosorbide (25 g) until dissolved. Labrafac Lipophile WL 1349 (25 g) is added to the solution Mixing is continued until a clear solution is obtained. Appropriate amount of solution may be filled into capsules to provide the desired dose.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsule formulations comprising dissolved hypolipemic drug and surfactant)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 44 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:396644 HCAPLUS Full-text
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2001037808 | A1 | 20010531 | WO 2000-US32255 | | 20001122 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | | |
| US 6248363 | B1 | 20010619 | US 1999-447690 | | 19991123 <-- |
| CA 2391923 | A1 | 20010531 | CA 2000-2391923 | | 20001122 <-- |
| EP 1233756 | A1 | 20020828 | EP 2000-980761 | | 20001122 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2003517470 | T | 20030527 | JP 2001-539423 | | 20001122 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-447690 | A | 19991123 <-- |
| | | | WO 2000-US32255 | W | 20001122 <-- |

ED Entered STN: 01 Jun 2001
AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and

triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 45 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:900426 HCAPLUS Full-text
DOCUMENT NUMBER: 134:46814
TITLE: Novel formulations comprising lipid-regulating agents containing fibrate and statin
INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| WO 2000076482 | A1 | 20001221 | WO 2000-US15717 | 20000608 <-- |
| W: CA, JP, MX | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 20010007670 | A1 | 20010712 | US 1999-330589 | 19990611 <-- |
| US 6372251 | B2 | 20020416 | | |
| CA 2376217 | A1 | 20001221 | CA 2000-2376217 | 20000608 <-- |
| EP 1185252 | A1 | 20020313 | EP 2000-938209 | 20000608 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2003520772 | T | 20030708 | JP 2001-502816 | 20000608 <-- |
| MX 2001PA12778 | A | 20020918 | MX 2001-PA12778 | 20011211 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-330589 A | 19990611 <-- |
| | | | WO 2000-US15717 W | 20000608 <-- |

ED Entered STN: 22 Dec 2000

AB The present invention is directed to a semi-solid formulation comprising a lipid-regulating agent, i.e. fibrate or statin. The formulation is prepared by solubilizing the lipid-regulating agent such as fenofibrate, pravastatin, or atorvastatin in one or more liquid components to form a clear liquid solution, then solidifying the solution by adding one or more solid or semi-solid components such as Cremophor RH40 or PEG to the solution to form a semi-solid formulation. The formulation can melt or dissolve upon mixing with a bulk aqueous medium. The resulting formulation results in an increase in drug solubility and oral bioavailability, and an improved dissoln. rate.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral semisolid dosage forms containing lipid-regulating agents)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 46 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:861475 HCAPLUS Full-text
DOCUMENT NUMBER: 134:32974
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Law, Devalina; Krill, Steven L.; Schmitt, Eric A.; Fort, James J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000072829 | A1 | 20001207 | WO 2000-US14109 | 20000523 <-- |
| W: CA, JP, MX | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2374117 | A1 | 20001207 | CA 2000-2374117 | 20000523 <-- |
| EP 1183017 | A1 | 20020306 | EP 2000-937680 | 20000523 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2003500439 | T | 20030107 | JP 2000-620941 | 20000523 <-- |
| MX 2001PA12225 | A | 20020812 | MX 2001-PA12225 | 20011128 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-323183 A | 19990528 <-- |
| | | | WO 2000-US14109 W | 20000523 <-- |

ED Entered STN: 08 Dec 2000
AB The present invention is directed to a solid formulation comprising the mixture of a lipid-regulating agent and an excipient, in which the agent and the excipient form a eutectic mixture Thus, fenofibrate and PEG (15:85) was heated to 85° until a clear solution was obtained. The solution was cooled to get a solid mass, which was ground and sieved through a 600-100 mesh screen. The solid was filled into capsules.
IT 42017-89-0, Fenofibric acid
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(formulations comprising lipid-regulating agents)
RN 42017-89-0 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)




IT 49562-28-9, FenoFibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulations comprising lipid-regulating agents)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 47 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:861472 HCAPLUS Full-text
DOCUMENT NUMBER: 134:32971
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Law, Devalina; Krill, Steven L.; Schmitt, Eric A.; Fort, James J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000072825 | A1 | 20001207 | WO 2000-US14106 | 20000523 <-- |
| W: CA, JP, MX | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 20010006662 | A1 | 20010705 | US 1999-320188 | 19990529 <-- |
| US 6465011 | B2 | 20021015 | | |
| CA 2374288 | A1 | 20001207 | CA 2000-2374288 | 20000523 <-- |
| EP 1183012 | A1 | 20020306 | EP 2000-932706 | 20000523 <-- |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

| | | | | | |
|---|---|---|---|---|---|
| JP 2003500437 | T | 20030107 | JP 2000-620937 | | 20000523 <-- |
| MX 2001PA12162 | A | 20020722 | MX 2001-PA12162 | | 20011127 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-320188 | A | 19990529 <-- |
| | | | WO 2000-US14106 | W | 20000523 <-- |

ED Entered STN: 08 Dec 2000

AB The present invention is directed to a solid formulation comprising the lipid-regulating agent dispersed in a hydrophilic, amorphous polymer in which the lipid-regulating agent is present as a metastable, amorphous phase. A mixture of fenofibrate and PVP (15:85) was dissolved in EtOH. The EtOH was evaporated and the solid mass was ground and sieved through a 60-100 mesh screen and the resulting granular formulation was filled into individual capsules.

IT 42017-89-0, Fenofibric acid 49562-28-9, Fenofibrate
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(formulations comprising lipid-regulating agents)

RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulations comprising lipid-regulating agents)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 48 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:707019 HCAPLUS Full-text
DOCUMENT NUMBER: 133:271719
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000057918 | A2 | 20001005 | WO 2000-US7459 | 20000321 <-- |
| WO 2000057918 | A3 | 20010118 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2367995 | A1 | 20001005 | CA 2000-2367995 | 20000321 <-- |
| EP 1165141 | A2 | 20020102 | EP 2000-919496 | 20000321 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002540174 | T | 20021126 | JP 2000-607667 | 20000321 <-- |
| MX 2001PA09839 | A | 20020621 | MX 2001-PA9839 | 20010928 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-283356 A | 19990331 <-- |
| | | | WO 2000-US7459 W | 20000321 <-- |

ED Entered STN: 06 Oct 2000
AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in a mixture of an oil and one or more surfactants to form a concentrate This concentrate forms fine and stable emulsions upon gentle mixing with water or any aqueous solns. Distillated acetylated monoglyceride (Myvacet 9-08) was mixed with propylene glycol laurate. Fenofibrate was then added to the mixture and mixed until completely dissolved. One drop of the solution was diluted with 10 mL of water to obtain a soft gelatin capsule.
IT 49562-28-9, Fenofibrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(lipid-regulating emulsions containing active agents and surfactants and oils)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid-regulating emulsions containing active agents and surfactants and oils)
RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 49 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:706964 HCAPLUS Full-text
DOCUMENT NUMBER: 133:271710
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Patel, Jitendra P.; Sanzgiri, Yeshwant D.; Lipari, John M.; Reiland, Thomas L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000057859 | A1 | 20001005 | WO 2000-US7650 | 20000323 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2365128 | A1 | 20001005 | CA 2000-2365128 | | 20000323 <-- |
| EP 1162954 | A1 | 20011219 | EP 2000-919545 | | 20000323 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | |
| JP 2003520767 | T | 20030708 | JP 2000-607610 | | 20000323 <-- |
| MX 2001PA09840 | A | 20020621 | MX 2001-PA9840 | | 20010928 <-- |
| PRIORITY APPLN. INFO.: | | | US 1999-282513 | A | 19990331 <-- |
| | | | WO 2000-US7650 | W | 20000323 <-- |

ED Entered STN: 06 Oct 2000

AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium. The emulsions result in an increase in drug solubility, oral bioavailability, and half-life. Pravastatin 1 g was dispersed in 24 g soybean oil and 2.5 g sorbitan monooleate, 0.5 g Polysorbate 80, and 72 g water were added with constant mixing until a uniform emulsion resulted.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable emulsions containing hypolipemics)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:441608 HCAPLUS Full-text
DOCUMENT NUMBER: 133:63989
TITLE: Novel formulations comprising lipid-regulating agents
INVENTOR(S): Lipari, John M.; Raymond, Dawn M.; Reiland, Tom
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2000037057 | A2 | 20000629 | WO 1999-US29696 | | 19991215 <-- |
| WO 2000037057 | A3 | 20001116 | | | |
| W: CA, JP, MX | | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | | |
| CA 2355820 | A1 | 20000629 | CA 1999-2355820 | | 19991215 <-- |
| EP 1140036 | A2 | 20011010 | EP 1999-967317 | | 19991215 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | | |
| JP 2002532539 | T | 20021002 | JP 2000-589168 | | 19991215 <-- |
| PRIORITY APPLN. INFO.: | | | US 1998-216448 | A | 19981218 <-- |
| | | | WO 1999-US29696 | W | 19991215 <-- |

ED Entered STN: 30 Jun 2000
AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one propylene glycol fatty acid ester as the primary solvent medium for the agent. One or more emulsifiers may be added to the formulation. Capmul PG8 (propylene glycol mono- and dicaprylate from Abitec) 8.3 g was mixed with 1 g Cremophor EL. Fenofibrate 0.7 g was then added to the above mixture The mixture was added to soft gelatin capsules using a syringe and the capsules were heat-sealed to give capsules containing 67 mg fenofibrate each.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsules containing lipid-regulating agents dissolved in propylene glycol fatty acid esters)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-

(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:193844 HCAPLUS Full-text
DOCUMENT NUMBER: 130:227739
TITLE: Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5883109 | A | 19990316 | US 1997-854311 | 19970512 <-- |
| PRIORITY APPLN. INFO.: | | | US 1997-854311 | 19970512 <-- |
| OTHER SOURCE(S): | MARPAT 130:227739 | | | |

ED Entered STN: 25 Mar 1999
AB A method is provided for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor, in combination with a cholesterol lowering drug, such as pravastatin. Capsules were prepared containing about 5 mg MTP inhibitor BMS 201,038.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:113552 HCAPLUS Full-text
DOCUMENT NUMBER: 130:173009
TITLE: Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
INVENTOR(S): Bova, David J.; Dunne, Josephine
PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9906046 | A1 | 19990211 | WO 1998-US15989 | 19980731 <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20010006644 | A1 | 20010705 | US 1997-903871 | 19970731 <-- |
| CA 2297764 | A1 | 19990211 | CA 1998-2297764 | 19980731 <-- |
| CA 2297764 | C | 20060110 | | |
| AU 9886800 | A | 19990222 | AU 1998-86800 | 19980731 <-- |
| EP 1003515 | A1 | 20000531 | EP 1998-938227 | 19980731 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| BR 9815549 | A | 20040622 | BR 1998-15549 | 19980731 <-- |
| NZ 525486 | A | 20051028 | NZ 1998-525486 | 19980731 <-- |
| EP 1743644 | A1 | 20070117 | EP 2006-17425 | 19980731 <-- |
| R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, | | | | |

NL, PT, SE
EP 1743630 A2 20070117 EP 2006-17607 19980731 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
NO 2000000407 A 20000316 NO 2000-407 20000127 <--
AU 2002300546 A1 20030213 AU 2002-300546 20020813 <--
AU 2002300546 B2 20060223
US 20050255158 A1 20051117 US 2005-71099 20050105 <--
PRIORITY APPLN. INFO.: US 1997-903871 A 19970731 <--
AU 1998-86800 A3 19980731 <--
EP 1998-938227 A3 19980731 <--
WO 1998-US15989 W 19980731 <--
ED Entered STN: 19 Feb 1999

AB The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl Me cellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals.

IT 49562-28-9, Fenofibrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral dosage forms containing HMG-CoA reductase inhibitors and nicotinate and lipid-altering agents for treating hyperlipidemia)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral dosage forms containing HMG-CoA reductase inhibitors and nicotinate for treating hyperlipidemia)
RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:113543 HCAPLUS Full-text
DOCUMENT NUMBER: 130:187186
TITLE: Pharmaceutical composition containing combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds for treating hyperlipidemia once a day at night
INVENTOR(S): Bova, David J.; Dunne, Josephine
PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9906035 | A2 | 19990211 | WO 1998-US15990 | 19980731 <-- |
| WO 9906035 | A3 | 19990422 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2298549 | A1 | 19990211 | CA 1998-2298549 | 19980731 <-- |

| | | | | | |
|---|---|---|---|---|---|
| CA 2298549 | C | 20060110 | | | |
| AU 9886801 | A | 19990222 | AU 1998-86801 | 19980731 | <-- |
| AU 752673 | B2 | 20020926 | | | |
| EP 1017390 | A2 | 20000712 | EP 1998-938228 | 19980731 | <-- |
| EP 1017390 | B1 | 20070418 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | | |
| BR 9815548 | A | 20001107 | BR 1998-15548 | 19980731 | <-- |
| JP 2001511444 | T | 20010814 | JP 2000-504849 | 19980731 | <-- |
| NZ 520176 | A | 20050225 | NZ 1998-520176 | 19980731 | <-- |
| AT 359785 | T | 20070515 | AT 1998-938228 | 19980731 | <-- |
| EP 1792616 | A1 | 20070606 | EP 2007-3276 | 19980731 | <-- |
| R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | | |
| ES 2283067 | T3 | 20071016 | ES 1998-938228 | 19980731 | <-- |
| NO 2000000439 | A | 20000322 | NO 2000-439 | 20000127 | <-- |
| AU 2002313846 | A1 | 20030403 | AU 2002-313846 | 20021205 | <-- |
| US 20040053975 | A1 | 20040318 | US 2003-260027 | 20030902 | <-- |
| PRIORITY APPLN. INFO.: | | | US 1997-903752 | A 19970731 | <-- |
| | | | AU 1998-86801 | A3 19980731 | <-- |
| | | | EP 1998-938228 | A3 19980731 | <-- |
| | | | WO 1998-US15990 | W 19980731 | <-- |

ED Entered STN: 19 Feb 1999

AB Solid pharmaceutical combinations for oral administration comprise nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals. A sustained-release tablet contained lovastatin 10.0, methocel E5 29.1, Pluracol E1450 0.9, and niacin 750 mg. The efficacy of the composition in lowering lipids profiles of patients over 43 wk is reported.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition containing combinations of HMG-CoA reductase

inhibitors and nicotinic acid compds. for treating hyperlipidemia once day at night)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:509103 HCAPLUS Full-text

DOCUMENT NUMBER: 129:156944

ORIGINAL REFERENCE NO.: 129:31837a,31840a

TITLE: Method for treating acid lipase deficiency diseases with a microsomal triglyceride transfer protein (MTP) inhibitor and cholesterol lowering drug

INVENTOR(S): Gregg, Richard E.; Wetterau, John R., II

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9831367 | A1 | 19980723 | WO 1998-US619 | 19980113 <-- |

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

| | | | | | | |
|---|---|---|---|---|---|---|
| US 6066653 | A | 20000523 | US 1998-5437 | | 19980110 | <-- |
| AU 9861315 | A | 19980807 | AU 1998-61315 | | 19980113 | <-- |
| PRIORITY APPLN. INFO.: | | | US 1997-36183P | P | 19970117 | <-- |
| | | | WO 1998-US619 | W | 19980113 | <-- |

OTHER SOURCE(S): MARPAT 129:156944
ED Entered STN: 17 Aug 1998
AB A method is provided for inhibiting or treating diseases associated with acid lipase deficiency by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acid lipase deficiency disease treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:509064 HCAPLUS Full-text
DOCUMENT NUMBER: 129:144862
ORIGINAL REFERENCE NO.: 129:29419a,29422a
TITLE: Method for treating or inhibiting phytosterolemia with

TI a microsomal triglyceride transfer protein (MTP) inhibitor and cholesterol lowering drug
INVENTOR(S): Gregg, Richard E.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9831225 | A1 | 19980723 | WO 1998-US618 | 19980113 <-- |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 6057339 | A | 20000502 | US 1998-5430 | 19980110 <-- |
| AU 9860232 | A | 19980807 | AU 1998-60232 | 19980113 <-- |
| PRIORITY APPLN. INFO.: | | | US 1997-35591P P | 19970117 <-- |
| | | | WO 1998-US618 W | 19980113 <-- |

OTHER SOURCE(S): MARPAT 129:144862
ED Entered STN: 17 Aug 1998
AB A method is provided for inhibiting onset or treating phytosterolemia by administering to a patient an MTP inhibitor, alone or, optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytosterolemia treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)
RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:87580 HCAPLUS Full-text
DOCUMENT NUMBER: 128:162883
ORIGINAL REFERENCE NO.: 128:31931a,31934a
TITLE: Method for lowering serum lipid levels employing a microsomal triglyceride-transfer protein (MTP) inhibitor in combination with another cholesterol-lowering drug
INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9803069 | A1 | 19980129 | WO 1997-US12229 | 19970714 <-- |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| ZA 9705950 | A | 19990104 | ZA 1997-5950 | 19970703 <-- |
| CA 2260995 | A1 | 19980129 | CA 1997-2260995 | 19970714 <-- |
| AU 9736624 | A | 19980210 | AU 1997-36624 | 19970714 <-- |
| AU 716145 | B2 | 20000217 | | |
| EP 1014791 | A1 | 20000705 | EP 1997-933435 | 19970714 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2000515526 | T | 20001121 | JP 1998-507023 | 19970714 <-- |

PRIORITY APPLN. INFO.: US 1996-22866P P 19960724 <--
WO 1997-US12229 W 19970714 <--
OTHER SOURCE(S): MARPAT 128:162883
ED Entered STN: 14 Feb 1998
AB A method is provided for lowering serum lipids, cholesterol, and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor in combination with a cholesterol lowering drug, e.g. pravastatin.
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microsomal triglyceride-transfer protein (MTP) inhibitor combination with cholesterol-lowering drug for lowering serum lipid level)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

# Search History

```
L1            1 SEA ABB=ON  PLU=ON  US2006-582410/APPS

     FILE 'REGISTRY' ENTERED AT 08:14:06 ON 18 NOV 2008
L2           53 SEA ABB=ON  PLU=ON  (102-71-6/BI OR 106392-12-5/BI OR 1066-33-7
                /BI OR 107-15-3/BI OR 111-42-2/BI OR 11137-98-7/BI OR 1305-62-0
                /BI OR 1309-42-8/BI OR 1310-58-3/BI OR 1310-65-2/BI OR
                1310-73-2/BI OR 1330-43-4/BI OR 1336-21-6/BI OR 1343-88-0/BI
                OR 134523-00-5/BI OR 134523-03-8/BI OR 141-43-5/BI OR 144-55-8/
                BI OR 147511-69-1/BI OR 14807-96-6/BI OR 24758-59-6/BI OR
                25013-16-5/BI OR 25322-68-3/BI OR 287714-41-4/BI OR 39366-43-3/
                BI OR 471-34-1/BI OR 49562-28-9/BI OR 497-19-8/BI OR 50-81-7/BI
                 OR 515-98-0/BI OR 546-93-0/BI OR 557-04-0/BI OR 56-87-1/BI OR
                6284-40-8/BI OR 63-42-3/BI OR 69-65-8/BI OR 74811-65-7/BI OR
                75330-75-5/BI OR 7664-41-7/BI OR 77-86-1/BI OR 77-92-9/BI OR
                7757-93-9/BI OR 7758-87-4/BI OR 7783-28-0/BI OR 79902-63-9/BI
                OR 81093-37-0/BI OR 874114-41-7/BI OR 9004-34-6/BI OR 9004-64-2
                /BI OR 9005-25-8/BI OR 9005-65-6/BI OR 9028-35-7/BI OR
                93957-54-1/BI)
L3              STRUCTURE UPLOADED
L4           50 SEA SSS SAM L3
L5            4 SEA ABB=ON  PLU=ON  L2 AND N=1 AND O=3
                D SCAN
L6            1 SEA ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)
                -"/CN
L7            2 SEA ABB=ON  PLU=ON  L2 AND N=2 AND O=5 AND NR=4
L8         1204 SEA ABB=ON  PLU=ON  77-86-1/CRN
L9            1 SEA ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPH
                ENYL)-B,Δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((P
                HENYLAMINO)CARBONYL)-, (BR,ΔR)-"/CN
                SEL RN
L10         131 SEA ABB=ON  PLU=ON  134523-00-5/CRN
L11           1 SEA ABB=ON  PLU=ON  L2 AND O=4 AND NR=2 AND CL=1
                E "PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYL-, 1-
L12           1 SEA ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHEN
                OXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
                SEL RN
L13          17 SEA ABB=ON  PLU=ON  49562-28-9/CRN

     FILE 'HCAPLUS' ENTERED AT 08:36:35 ON 18 NOV 2008
L14       10674 SEA ABB=ON  PLU=ON  (L6 OR L8)
L15        4140 SEA ABB=ON  PLU=ON  (L9 OR L10)
L16        1868 SEA ABB=ON  PLU=ON  (L12 OR L13)
L17           9 SEA ABB=ON  PLU=ON  L14 AND L15 AND L16
L18           1 SEA ABB=ON  PLU=ON  L17 AND L1

     FILE 'BIOSIS, EMBASE, DRUGU, MEDLINE, TOXCENTER' ENTERED AT 10:31:04 ON
     18 NOV 2008
L19       12476 SEA ABB=ON  PLU=ON  (L6 OR L8)
L20       18785 SEA ABB=ON  PLU=ON  (L9 OR L10)
L21        9094 SEA ABB=ON  PLU=ON  (L12 OR L13)
L22           8 SEA ABB=ON  PLU=ON  L19 AND L20 AND L21
L23        1535 SEA ABB=ON  PLU=ON  L15 AND L16
L24        1527 SEA ABB=ON  PLU=ON  L23 NOT L19

     FILE 'REGISTRY' ENTERED AT 10:36:15 ON 18 NOV 2008
```

```
L25           0 SEA ABB=ON  PLU=ON  L4 AND L2
L26        2792 SEA SSS FUL L3
L27           4 SEA ABB=ON  PLU=ON  L2 AND L26

     FILE 'HCAPLUS' ENTERED AT 10:39:43 ON 18 NOV 2008
L28         406 SEA ABB=ON  PLU=ON  HOLM P?/AU
L29          32 SEA ABB=ON  PLU=ON  NORLING T?/AU
L30           1 SEA ABB=ON  PLU=ON  (L28 OR L29) AND L17

     FILE 'BIOSIS, EMBASE, DRUGU, MEDLINE, TOXCENTER' ENTERED AT 10:42:09 ON
     18 NOV 2008
L31           0 SEA ABB=ON  PLU=ON  (L28 OR L29) AND L22

     FILE 'REGISTRY' ENTERED AT 12:30:21 ON 18 NOV 2008
L32             STRUCTURE UPLOADED
L33          50 SEA SUB=L26 SSS SAM L32
L34        1370 SEA SUB=L26 SSS FUL L32
L35             STRUCTURE UPLOADED
L36          13 SEA SUB=L26 SSS SAM L35
L37         321 SEA SUB=L26 SSS FUL L35
L38             STRUCTURE UPLOADED
L39        1104 SEA SUB=L26 SSS FUL L38

     FILE 'HCAPLUS' ENTERED AT 12:33:48 ON 18 NOV 2008
L40           9 SEA ABB=ON  PLU=ON  L34 AND L37 AND L39
L41           2 SEA ABB=ON  PLU=ON  L37(L)L39
L42         347 SEA ABB=ON  PLU=ON  L37 AND L39
L43         250 SEA ABB=ON  PLU=ON  L42 AND (PRY<=2005 OR AY<=2005 OR PY<=2005)

L44           1 SEA ABB=ON  PLU=ON  (L28 OR L29) AND L17
L45           1 SEA ABB=ON  PLU=ON  (L30 OR L44)
L46         152 SEA ABB=ON  PLU=ON  L43 AND 63/SC,SX
L47      243067 SEA ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+NT/CT
L48         111 SEA ABB=ON  PLU=ON  L46 AND L47
L49       49418 SEA ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+NT/CT(L)(CAPSULE/OBI
                OR SACHET/OBI OR TABLET/OBI)
L50          60 SEA ABB=ON  PLU=ON  L46 AND L49

     FILE 'HCAPLUS' ENTERED AT 12:52:12 ON 18 NOV 2008
L51           1 DUP REM L45 L31 (0 DUPLICATES REMOVED)

     FILE 'HCAPLUS' ENTERED AT 12:52:28 ON 18 NOV 2008
L52           8 SEA ABB=ON  PLU=ON  L17 NOT L45

     FILE 'BIOSIS, EMBASE, MEDLINE, TOXCENTER, DRUGU' ENTERED AT 12:52:55 ON
     18 NOV 2008
L53           8 SEA ABB=ON  PLU=ON  L22 NOT L31

     FILE 'HCAPLUS, TOXCENTER' ENTERED AT 12:53:19 ON 18 NOV 2008
L54           9 DUP REM L52 L53 (7 DUPLICATES REMOVED)

     FILE 'HCAPLUS' ENTERED AT 12:54:17 ON 18 NOV 2008
L55          56 SEA ABB=ON  PLU=ON  L50 NOT (L45 OR L52 OR L53)
```